Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Agenus Inc. (AGEN)
USD4.83
-0.26 (-5.02%)
US NASDAQ Healthcare Biotechnology
Address
3 Forbes Road 02421-7305
Lexington, MA, US
Lexington, MA, US
CEO
Garo H. Armen
Website
agenusbio.com
IPO
2000-02-08
CIK 1098972 ISIN US00847G8042
Description
Agenus Inc. is a clinical-stage biotechnology firm operating globally, dedicated to the discovery and development of immuno-oncology therapies. The company's innovative technological arsenal includes Retrocyte Display, a sophisticated antibody expression platform designed to identify fully human and humanized monoclonal antibodies, alongside other proprietary display technologies. Agenus is also actively involved in vaccine development programs, featuring the Prophage vaccine candidate and QS-21 Stimulon, a widely recognized saponin-based vaccine adjuvant. Its robust and diverse pipeline of therapeutic candidates targets various immune checkpoints and cancer pathways. Notable assets in clinical development include: Balstilimab: An anti-PD-1 antagonist that has successfully completed Phase II trials for the treatment of second-line cervical cancer. AGEN1181: A monospecific anti-CTLA-4 antibody currently undergoing Phase 1/2 clinical evaluation. AGEN2373: An anti-CD137 monospecific antibody in Phase 1 clinical trials. AGEN1423: A bi-functional anti-CD73/TGFß TRAP antibody, engineered to modulate the tumor microenvironment, which has concluded Phase 1 studies. AGEN1777: An anti-TIGIT bispecific antibody. AGEN1327: A human monoclonal antibody. INCAGN1876: An anti-GITR monospecific antibody. INCAGN1949: An anti-OX40 monospecific antibody. INCAGN2390: An anti-TIM-3 monospecific antibody. INCAGN2385: An anti-LAG-3 monospecific antibody. MK-4830: A monospecific antibody engineered to target ILT4. AGENT 797: An iNKT cell therapy, currently in Phase 1 for solid tumors, multiple myeloma, and viral ARDS, with ongoing clinical investigation for hematological malignancies and multiple myeloma/B cell indications. AGEN1884: A first-generation anti-CTLA-4 monospecific antibody. Agenus Inc. utilizes a portfolio of trademarks, including ASV, AutoSynVax, EVAMPLIX, MiNK, PSV, PhosPhoSynVax, Prophage, Retrocyte Display, and Stimulon, alongside its own company name. Strategic alliances are maintained with partners such as Incyte Corporation, Merck Sharpe & Dohme, Recepta Biopharma SA, and Gilead Sciences, Inc. Established in 1994, the company originally operated as Antigenics Inc. before rebranding to Agenus Inc. in January 2011. Its corporate headquarters are situated in Lexington, Massachusetts.
News Sentiment (7d)
Based on only 1 article — low confidence
Market Cap & Enterprise Value
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD4.83
-0.26 (-5.02%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
942.7K
Beta
1.54
Float Shares
35.62M
Free Float %
92.8%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -14.66% | -16.41% | -17.68% | +14.39% | -26.41% | +3.82% | -6.86% | -88.52% | -94.62% | -95.12% | -99.96% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (11 ratings, all time)
Buy
Price Targets & DCF
Current price
4.83
Low
7.00
+45.1%
Consensus
7.33
+51.9%
Median
7.00
+45.1%
High
8.00
+65.8%
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 2 | 0 |
| Hold | 0 | -1 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | — | — |
| Last Year | — | — |
| All Time | 5 |
10.20
+111.4%
|
Quality scores
Altman Z-Score
-14.54
Distress
Piotroski F-Score
5 / 9
Average
MOAT Score
1 / 10
No MOAT
Composite Rating
C+
Overall Score
2 / 5
Medium
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
5 / 5
High
D/E Score
1 / 5
Low
P/E Score
3 / 5
Medium
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%+10.4% ★ Q1'26: +40.2% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%+100.0% ★ Q1'26: +199.0% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-34.5% Q1'26: -106.6% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%-18.0% Q1'26: +0.0% (vs Q1'25)
-
ROIC Biotechnology: -16.1%-38.0%
-
Share dilution Biotechnology: -3.4%+38.5% Q1'26: +56.5% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-31.72× Q1'26: 0.16× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2008 actual |
Dec 2010 actual |
Dec 2012 actual |
Dec 2014 actual |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 2 Rev. Ana. 1 EPS Ana. |
Dec 2028 2 Rev. Ana. 2 EPS Ana. |
Dec 2029 1 Rev. Ana. 1 EPS Ana. |
Dec 2030 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
2.65M
est: 2.92M (-9.3%)
|
3.36M
est: 3.85M (-12.8%)
|
15.96M
est: 15.65M (+2.0%)
|
6.98M
est: 15.89M (-56.1%)
|
24.82M
est: 24.08M (+3.0%)
|
22.57M
est: 24.11M (-6.4%)
|
42.88M
est: 49.40M (-13.2%)
|
36.78M
est: 36.99M (-0.6%)
|
150.05M
est: 124.22M (+20.8%)
|
88.17M
est: 74.60M (+18.2%)
|
295.67M
est: 313.14M (-5.6%)
|
98.02M
est: 82.52M (+18.8%)
|
156.31M
est: 159.63M (-2.1%)
|
103.46M
est: 106.42M (-2.8%)
|
114.20M
est: 108.09M (+5.6%)
|
232.90M
230.95M – 234.85M
+115.5% YoY
|
125.40M
119.86M – 130.94M
-46.2% YoY
|
108.20M
108.15M – 108.25M
-13.7% YoY
|
125.90M
124.85M – 126.95M
+16.4% YoY
|
172.50M
171.06M – 173.94M
+37.0% YoY
|
| EBITDA |
-37.84M
est: -6.26M (-504.4%)
|
-13.60M
est: -12.42M (-9.5%)
|
-4.98M
est: 9.56M (-152.2%)
|
-39.64M
est: -32.36M (-22.5%)
|
-84.71M
est: -18.13M (-367.2%)
|
-104.73M
est: -18.15M (-477.0%)
|
-95.82M
est: -37.19M (-157.6%)
|
-130.48M
est: -27.85M (-368.5%)
|
-63.45M
est: -93.52M (+32.2%)
|
-114.63M
est: -56.17M (-104.1%)
|
43.78M
est: -235.76M (+118.6%)
|
-161.85M
est: 4.51M (-3,689.6%)
|
-145.92M
est: -91.21M (-60.0%)
|
-101.30M
est: -60.81M (-66.6%)
|
-10.56M
est: -61.76M (+82.9%)
|
-133.08M
-134.19M – -131.96M
-115.5% YoY
|
-71.65M
-74.82M – -68.49M
+46.2% YoY
|
-61.83M
-61.85M – -61.80M
+13.7% YoY
|
-71.94M
-72.54M – -71.34M
-16.4% YoY
|
-98.57M
-99.39M – -97.74M
-37.0% YoY
|
| EBIT |
-37.84M
est: -42.59M (+11.1%)
|
-17.03M
est: -22.19M (+23.2%)
|
-6.63M
est: 6.67M (-199.4%)
|
-41.22M
est: -46.69M (+11.7%)
|
-86.67M
est: -18.66M (-364.4%)
|
-109.68M
est: -18.68M (-487.0%)
|
-101.82M
est: -38.28M (-166.0%)
|
-136.77M
est: -28.66M (-377.1%)
|
-70.11M
est: -96.26M (+27.2%)
|
-121.81M
est: -57.81M (-110.7%)
|
37.00M
est: -242.67M (+115.2%)
|
-168.79M
est: 35.54M (-575.0%)
|
-159.51M
est: -97.53M (-63.6%)
|
-114.65M
est: -65.02M (-76.3%)
|
-20.56M
est: -66.04M (+68.9%)
|
-142.30M
-143.49M – -141.10M
-115.5% YoY
|
-76.62M
-80.00M – -73.23M
+46.2% YoY
|
-66.11M
-66.14M – -66.08M
+13.7% YoY
|
-76.92M
-77.57M – -76.28M
-16.4% YoY
|
-105.39M
-106.28M – -104.51M
-37.0% YoY
|
| Net Income |
-28.70M
est: -17.96M (-59.8%)
|
-21.91M
est: -21.00M (-4.3%)
|
-11.33M
est: 208.8K (-5,523.0%)
|
-42.49M
est: -35.59M (-19.4%)
|
-87.88M
est: -443.34M (+80.2%)
|
-127.00M
est: -611.92M (+79.2%)
|
-120.69M
est: -486.05M (+75.2%)
|
-159.69M
est: -566.82M (+71.8%)
|
-107.66M
est: -436.88M (+75.4%)
|
-180.91M
est: -452.34M (+60.0%)
|
-23.93M
est: -15.80M (-51.4%)
|
-220.07M
est: -262.80M (+16.3%)
|
-245.76M
est: -334.31M (+26.5%)
|
-227.21M
est: -357.34M (+36.4%)
|
115.0K
est: -26.66M (+100.4%)
|
38.65M
38.23M – 39.08M
+245.0% YoY
|
-21.71M
-21.94M – -21.47M
-156.2% YoY
|
-45.79M
-62.96M – -28.62M
-111.0% YoY
|
-30.33M
-30.66M – -30.00M
+33.8% YoY
|
-3.27M
-3.31M – -3.24M
+89.2% YoY
|
| SGA |
19.83M
est: 1.73M (+1,047.9%)
|
12.11M
est: 2.28M (+432.0%)
|
11.47M
est: 9.25M (+24.0%)
|
21.25M
est: 9.39M (+126.4%)
|
28.37M
est: 14.23M (+99.3%)
|
33.13M
est: 14.25M (+132.5%)
|
33.74M
est: 29.19M (+15.6%)
|
37.34M
est: 21.86M (+70.8%)
|
46.04M
est: 73.41M (-37.3%)
|
59.22M
est: 44.08M (+34.3%)
|
76.36M
est: 185.05M (-58.7%)
|
81.01M
est: 63.66M (+27.2%)
|
78.74M
est: 85.30M (-7.7%)
|
71.88M
est: 56.87M (+26.4%)
|
44.39M
est: 57.76M (-23.1%)
|
124.45M
123.41M – 125.50M
+115.5% YoY
|
67.01M
64.05M – 69.97M
-46.2% YoY
|
57.82M
57.79M – 57.85M
-13.7% YoY
|
67.28M
66.71M – 67.84M
+16.4% YoY
|
92.18M
91.41M – 92.95M
+37.0% YoY
|
| EPS |
-2.72
est: -4.85 (+43.9%)
|
-1.36
est: -1.37 (+0.4%)
|
-0.48
est: -1.59 (+69.7%)
|
-14.22
est: -0.70 (-1,946.0%)
|
-22.47
est: -20.65 (-8.8%)
|
-29.17
est: -28.50 (-2.4%)
|
-24.53
est: -22.64 (-8.4%)
|
-28.83
est: -26.40 (-9.2%)
|
-22.10
est: -20.35 (-8.6%)
|
-21.00
est: -21.07 (+0.3%)
|
-2.11
est: -0.74 (-186.7%)
|
-15.64
est: -14.85 (-5.3%)
|
-13.75
est: -11.24 (-22.3%)
|
-10.59
est: -12.02 (+11.9%)
|
0.00
est: -0.90 (+99.6%)
|
1.30
1.29 – 1.31
+245.0% YoY
|
-0.73
-0.74 – -0.72
-156.2% YoY
|
-1.54
-2.12 – -0.96
-111.0% YoY
|
-1.02
-1.03 – -1.01
+33.8% YoY
|
-0.11
-0.11 – -0.11
+89.2% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | C+ | 2/5 | 1/5 | 1/5 | 5/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-08 | C- | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | C- | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | C- | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | C- | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | C- | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-01 | C- | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | C- | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | C- | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | C- | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | C- | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | C- | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | C- | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | C- | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | C- | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | C- | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | C- | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | C- | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-152.68M
OE per share TTM
-4.42
Owner's Yield
-123.44%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
68.0%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
10
Total invested
227.3K
Insider transactions (90d)
10
Beneficial owners (>5%)
35
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2 | 28.27M | 6.80% | — | 28.27M | — | — | PN | Delaware | 2024-02-21 | ↗ |
| 2 | Agenus Inc. (“Agenus”) | 26.33M | 79.80% | 26.33M | — | 26.33M | — | CO | — | 2021-10-28 | ↗ |
| 3 | STATE STREET CORPORATION | 21.17M | 8.24% | — | 20.79M | — | 21.17M | HC | BOSTON MASSACHUSETTS | 2022-02-11 | ↗ |
| 4 | The Vanguard Group - 23-1945930 | 17.63M | 6.87% | — | 413.9K | 17.05M | 582.1K | IA | Pennsylvania | 2022-02-09 | ↗ |
| 5 | SSGA FUNDS MANAGEMENT, INC. | 17.31M | 6.74% | — | 17.26M | — | 17.31M | IA | BOSTON MASSACHUSETTS | 2022-02-11 | ↗ |
| 6 | Artal Group S.A. | 15.63M | 5.10% | 15.63M | — | 15.63M | — | OO | Bermuda | 2023-02-01 | ↗ |
| 7 | Artal International Management S.A. | 15.63M | 5.10% | 15.63M | — | 15.63M | — | OO | Bermuda | 2023-02-01 | ↗ |
| 8 | Artal International S.C.A. | 15.63M | 5.10% | 15.63M | — | 15.63M | — | OO | Bermuda | 2023-02-01 | ↗ |
| 9 | Invus Public Equities Advisors, LLC | 15.63M | 5.10% | 15.63M | — | 15.63M | — | OO | Bermuda | 2023-02-01 | ↗ |
| 10 | Invus Public Equities, L.P. | 15.63M | 5.10% | 15.63M | — | 15.63M | — | PN | Bermuda | 2023-02-01 | ↗ |
| 11 | Mr. Amaury Wittouck | 15.63M | 5.10% | 15.63M | — | 15.63M | — | IN | Bermuda | 2023-02-01 | ↗ |
| 12 | Stichting Administratiekantoor Westend | 15.63M | 5.10% | 15.63M | — | 15.63M | — | OO | Bermuda | 2023-02-01 | ↗ |
| 13 | Westend S.A. | 15.63M | 5.10% | 15.63M | — | 15.63M | — | OO | Bermuda | 2023-02-01 | ↗ |
| 14 | David Kroin | 15.23M | 5.92% | — | 15.23M | — | — | HC, IN | United States | 2022-04-08 | ↗ |
| 15 | Deep Track Biotechnology Master Fund, Ltd. | 15.23M | 5.92% | — | 15.23M | — | — | CO | Cayman Islands | 2022-04-08 | ↗ |
| 16 | Deep Track Capital, LP | 15.23M | 5.92% | — | 15.23M | — | — | IA, OO | Delaware | 2022-04-08 | ↗ |
| 17 | Incyte Corporation | 14.06M | 7.40% | 14.06M | — | 14.06M | — | CO | Delaware | 2021-02-11 | ↗ |
| 18 | RTW Investments, LP | 12.86M | 6.76% | — | 12.86M | — | 12.86M | IA, OO | OR PLACE OF ORGANIZATION | 2021-02-12 | ↗ |
| 19 | Roderick Wong | 12.86M | 6.76% | — | 12.86M | — | 12.86M | HC, IN | OR PLACE OF ORGANIZATION | 2021-02-12 | ↗ |
| 20 | Gilead Sciences, Inc. | 11.11M | 4.30% | 11.11M | — | 11.11M | — | CO | State of Delaware | 2022-02-17 | ↗ |
| 21 | Larry N. Feinberg | 9.11M | 3.55% | 627.9K | 8.48M | 627.9K | 8.48M | IN | United States | 2022-02-11 | ↗ |
| 22 | Oracle Investment Management, Inc. | 8.42M | 3.28% | — | 8.42M | — | 8.42M | CO | United States | 2022-02-11 | ↗ |
| 23 | RTW Master Fund, Ltd. | 8.20M | 4.31% | — | 8.20M | — | 8.20M | CO | OR PLACE OF ORGANIZATION | 2021-02-12 | ↗ |
| 24 | Oracle Associates, LLC | 8.14M | 3.17% | — | 8.14M | — | 8.14M | OO | United States | 2022-02-11 | ↗ |
| 25 | Bihua Chen | 7.00M | 3.70% | — | 7.00M | — | 7.00M | IN | United States | 2021-02-16 | ↗ |
| 26 | Cormorant Asset Management, LP | 7.00M | 3.70% | — | 7.00M | — | 7.00M | PN | Delaware | 2021-02-16 | ↗ |
| 27 | Cormorant Global Healthcare GP, LLC | 6.74M | 3.50% | — | 6.74M | — | 6.74M | OO | Delaware | 2021-02-16 | ↗ |
| 28 | Cormorant Global Healthcare Master Fund, LP | 6.74M | 3.50% | — | 6.74M | — | 6.74M | PN | Cayman Islands | 2021-02-16 | ↗ |
| 29 | Oracle Partners, L.P. | 5.89M | 2.29% | — | 5.89M | — | 5.89M | PN | United States | 2022-02-11 | ↗ |
| 30 | (1) BlackRock, Inc. | 1.58M | 7.30% | 1.55M | — | 1.58M | — | HC | Delaware | 2024-11-08 | ↗ |
| 31 | Oracle Ten Fund, L.P. | 1.40M | 0.55% | — | 1.40M | — | 1.40M | PN | United States | 2022-02-11 | ↗ |
| 32 | Oracle Institutional Partners, L.P. | 845.5K | 0.33% | — | 845.5K | — | 845.5K | PN | United States | 2022-02-11 | ↗ |
| 33 | Plan | 278.0K | 0.15% | — | 278.0K | — | 278.0K | OO | Delaware | 2021-02-16 | ↗ |
| 34 | Employees’ Retirement Plan | 278.0K | 0.11% | — | 278.0K | — | 278.0K | OO | United States | 2022-02-11 | ↗ |
| 35 | The Feinberg Family Foundation | 62.0K | 0.02% | — | 62.0K | — | 62.0K | OO | United States | 2022-02-11 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
10
-91 vs prev Q
New positions
0
Closed positions
86
Increased
2
Reduced
3
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | EP WEALTH ADVISORS, LLC | 10.0K +10.0K (+100.0%) | 31.40M +31.4M (+100.0%) | 0.03% +0.031 pp | 0.00% +0.000 pp | USD3.14 +0.0% | 1 qtrs NEW |
| 2 | VANGUARD GROUP INC | 2.83M +261.2K (+10.2%) | 8.89M -1.0M (-10.2%) | 8.88% -0.261 pp | 0.00% +0.000 pp | USD13.41 -76.6% | 7 qtrs — |
| 3 | SIREN, L.L.C. | 1.06M +— (+0.0%) | 3.34M -755.6K (-18.4%) | 3.34% -0.447 pp | 0.10% -0.061 pp | USD3.13 +0.3% | 6 qtrs — |
| 4 | ACADIAN ASSET MANAGEMENT LLC | 622.5K +417.4K (+203.5%) | 1.95M +1.2M (+148.5%) | 1.95% +1.223 pp | 0.00% +0.002 pp | USD3.37 -6.8% | 6 qtrs — |
| 5 | BLACKROCK, INC. | 558.3K +11.2K (+2.1%) | 1.75M -353.2K (-16.8%) | 1.75% -0.195 pp | 0.00% +0.000 pp | USD5.00 -37.2% | 6 qtrs — |
| 6 | RENAISSANCE TECHNOLOGIES LLC | 543.5K +477.3K (+721.1%) | 1.71M +1.5M (+569.6%) | 1.70% +1.469 pp | 0.00% +0.002 pp | USD3.23 -2.8% | 2 qtrs — |
| 7 | GEODE CAPITAL MANAGEMENT, LLC | 372.7K +25.8K (+7.4%) | 1.17M -165.1K (-12.4%) | 1.17% -0.065 pp | 0.00% +0.000 pp | USD12.55 -75.0% | 7 qtrs — |
| 8 | MORGAN STANLEY | 285.2K -263.9K (-48.1%) | 895.5K -1.2M (-57.6%) | 0.89% -1.059 pp | 0.00% 0.000 pp | USD8.50 -63.1% | 7 qtrs — |
| 9 | MILLENNIUM MANAGEMENT LLC | 225.3K -123.4K (-35.4%) | 707.6K -635.1K (-47.3%) | 0.71% -0.534 pp | 0.00% 0.000 pp | USD4.57 -31.3% | 3 qtrs — |
| 10 | JUMP FINANCIAL, LLC | 170.4K +28.9K (+20.4%) | 535.1K -9.7K (-1.8%) | 0.53% +0.031 pp | 0.01% +0.000 pp | USD3.78 -16.9% | 3 qtrs — |
| 11 | PANAGORA ASSET MANAGEMENT INC | 163.1K +37.0K (+29.3%) | 512.3K +26.5K (+5.5%) | 0.51% +0.063 pp | 0.00% 0.000 pp | USD3.69 -14.9% | 2 qtrs — |
| 12 | MARSHALL WACE, LLP | 146.8K +33.5K (+29.6%) | 461.0K +24.7K (+5.7%) | 0.46% +0.057 pp | 0.00% +0.000 pp | USD4.24 -25.9% | 3 qtrs — |
| 13 | RAYMOND JAMES FINANCIAL INC | 141.7K -4.1K (-2.8%) | 444.8K -116.4K (-20.7%) | 0.44% -0.074 pp | 0.00% +0.000 pp | USD3.85 -18.4% | 3 qtrs — |
| 14 | STATE STREET CORP | 137.4K -13.2K (-8.8%) | 431.4K -148.4K (-25.6%) | 0.43% -0.105 pp | 0.00% +0.000 pp | USD12.99 -75.8% | 7 qtrs — |
| 15 | D. E. SHAW & CO., INC. | 127.6K +13.3K (+11.6%) | 400.8K -39.4K (-8.9%) | 0.40% -0.006 pp | 0.00% +0.000 pp | USD3.78 -16.9% | 2 qtrs — |
| 16 | WALLEYE CAPITAL LLC | 123.5K -187.3K (-60.3%) | 387.7K -808.9K (-67.6%) | 0.39% -0.718 pp | 0.00% -0.003 pp | USD4.31 -27.1% | 3 qtrs — |
| 17 | UBS GROUP AG | 118.8K +36.9K (+45.0%) | 373.1K +57.6K (+18.3%) | 0.37% +0.081 pp | 0.00% +0.000 pp | USD3.40 -7.6% | 7 qtrs — |
| 18 | TWO SIGMA INVESTMENTS, LP | 117.1K +14.8K (+14.4%) | 367.7K -26.3K (-6.7%) | 0.37% +0.003 pp | 0.00% 0.000 pp | USD3.76 -16.5% | 2 qtrs — |
| 19 | 683 CAPITAL MANAGEMENT, LLC | 114.3K +114.3K (+100.0%) | 359.0K +359.0K (+100.0%) | 0.36% +0.359 pp | 0.02% +0.016 pp | USD3.14 +0.0% | 1 qtrs NEW |
| 20 | MAN GROUP PLC | 114.2K +114.2K (+100.0%) | 358.6K +358.6K (+100.0%) | 0.36% +0.358 pp | 0.00% +0.001 pp | USD3.14 +0.0% | 1 qtrs NEW |
| 21 | POINT72 ASSET MANAGEMENT, L.P. | 108.2K +108.2K (+100.0%) | 339.8K +339.8K (+100.0%) | 0.34% +0.339 pp | 0.00% +0.000 pp | USD3.14 +0.0% | 1 qtrs NEW |
| 22 | OMERS ADMINISTRATION CORP | 100.5K +100.5K (+100.0%) | 315.6K +315.6K (+100.0%) | 0.32% +0.315 pp | 0.00% +0.002 pp | USD3.14 +0.0% | 1 qtrs NEW |
| 23 | NORTHERN TRUST CORP | 89.6K +7.9K (+9.7%) | 281.3K -33.2K (-10.6%) | 0.28% -0.010 pp | 0.00% +0.000 pp | USD12.01 -73.9% | 7 qtrs — |
| 24 | CITADEL ADVISORS LLC | 88.3K -21.7K (-19.7%) | 277.3K -146.2K (-34.5%) | 0.28% -0.114 pp | 0.00% +0.000 pp | USD5.87 -46.5% | 7 qtrs — |
| 25 | JANE STREET GROUP, LLC | 73.6K +20.8K (+39.4%) | 231.0K +27.8K (+13.7%) | 0.23% +0.043 pp | 0.00% +0.000 pp | USD3.65 -14.0% | 2 qtrs — |
| 26 | CONNOR, CLARK & LUNN INVESTMENT MANAGEMENT LTD. | 68.0K +68.0K (+100.0%) | 213.4K +213.4K (+100.0%) | 0.21% +0.213 pp | 0.00% +0.001 pp | USD3.14 +0.0% | 1 qtrs NEW |
| 27 | CANADA PENSION PLAN INVESTMENT BOARD | 66.1K +66.1K (+100.0%) | 207.6K +207.6K (+100.0%) | 0.21% +0.207 pp | 0.00% +0.000 pp | USD3.14 +0.0% | 1 qtrs NEW |
| 28 | GOLDMAN SACHS GROUP INC | 61.7K +16.0K (+35.1%) | 193.9K +17.9K (+10.2%) | 0.19% +0.031 pp | 0.00% +0.000 pp | USD4.10 -23.4% | 6 qtrs — |
| 29 | SUSQUEHANNA PORTFOLIO STRATEGIES, LLC | 59.4K -108.8K (-64.7%) | 186.6K -461.1K (-71.2%) | 0.19% -0.412 pp | 0.00% -0.007 pp | USD4.37 -28.1% | 3 qtrs — |
| 30 | SQUAREPOINT OPS LLC | 55.1K +41.2K (+294.9%) | 173.1K +119.4K (+222.1%) | 0.17% +0.123 pp | 0.00% +0.000 pp | USD3.32 -5.4% | 2 qtrs — |
| 31 | EXODUSPOINT CAPITAL MANAGEMENT, LP | 47.5K +47.5K (+100.0%) | 149.0K +149.0K (+100.0%) | 0.15% +0.149 pp | 0.00% +0.001 pp | USD3.14 +0.0% | 1 qtrs NEW |
| 32 | BARCLAYS PLC | 46.3K +18.5K (+66.4%) | 145.3K -7.1K (-4.7%) | 0.15% +0.046 pp | 0.00% +0.000 pp | USD3.57 -12.0% | 7 qtrs — |
| 33 | AVESTAR CAPITAL, LLC | 41.0K +— (+0.0%) | 128.7K -29.1K (-18.4%) | 0.13% -0.017 pp | 0.01% -0.002 pp | USD16.69 -81.2% | 7 qtrs — |
| 34 | QUBE RESEARCH & TECHNOLOGIES LTD | 39.9K +39.9K (+100.0%) | 125.3K +125.3K (+100.0%) | 0.13% +0.125 pp | 0.00% +0.000 pp | USD3.14 +0.0% | 1 qtrs NEW |
| 35 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 36.1K -7.3K (-16.8%) | 113.4K -53.7K (-32.2%) | 0.11% -0.041 pp | 0.00% +0.000 pp | USD16.69 -81.2% | 7 qtrs — |
| 36 | ENGINEERS GATE MANAGER LP | 35.3K +25.0 (+0.1%) | 110.8K -25.0K (-18.4%) | 0.11% -0.015 pp | 0.00% 0.000 pp | USD4.33 -27.5% | 3 qtrs — |
| 37 | VIRTU FINANCIAL LLC | 34.4K +34.4K (+100.0%) | 108.0K +108.0K (+100.0%) | 0.11% +0.108 pp | 0.00% +0.004 pp | USD3.14 +0.0% | 1 qtrs NEW |
| 38 | TWO SIGMA ADVISERS, LP | 34.2K +34.2K (+100.0%) | 107.5K +107.5K (+100.0%) | 0.11% +0.107 pp | 0.00% +0.000 pp | USD3.14 +0.0% | 1 qtrs NEW |
| 39 | GRAHAM CAPITAL MANAGEMENT, L.P. | 31.7K -23.1K (-42.2%) | 99.6K -111.5K (-52.8%) | 0.10% -0.096 pp | 0.00% -0.001 pp | USD3.85 -18.4% | 2 qtrs — |
| 40 | OVATA CAPITAL MANAGEMENT LTD | 30.8K +30.8K (+100.0%) | 96.7K +96.7K (+100.0%) | 0.10% +0.097 pp | 0.01% +0.012 pp | USD3.14 +0.0% | 7 qtrs — |
| 41 | CAPTRUST FINANCIAL ADVISORS | 30.1K -597.0 (-1.9%) | 94.5K -23.7K (-20.0%) | 0.09% -0.015 pp | 0.00% 0.000 pp | USD4.57 -31.3% | 3 qtrs — |
| 42 | KEY CLIENT FIDUCIARY ADVISORS, LLC | 27.3K -11.9K (-30.3%) | 85.9K -65.2K (-43.1%) | 0.09% -0.054 pp | 0.03% -0.021 pp | USD16.55 -81.0% | 7 qtrs — |
| 43 | ADVISOR GROUP HOLDINGS, INC. | 27.1K -6.8K (-20.1%) | 85.2K -55.3K (-39.4%) | 0.09% -0.036 pp | 0.00% 0.000 pp | USD6.45 -51.3% | 7 qtrs — |
| 44 | HIGHTOWER ADVISORS, LLC | 25.1K -150.0 (-0.6%) | 78.9K -18.4K (-18.9%) | 0.08% -0.011 pp | 0.00% +0.000 pp | USD12.63 -75.1% | 7 qtrs — |
| 45 | PRICE T ROWE ASSOCIATES INC /MD/ | 24.5K +24.5K (+100.0%) | 77.0K +77.0K (+100.0%) | 0.08% +0.077 pp | 0.00% +0.000 pp | USD3.14 +0.0% | 1 qtrs NEW |
| 46 | LPL FINANCIAL LLC | 23.3K +3.9K (+20.3%) | 73.2K -1.4K (-1.9%) | 0.07% +0.004 pp | 0.00% +0.000 pp | USD4.10 -23.4% | 3 qtrs — |
| 47 | GROUP ONE TRADING, L.P. | 22.2K +22.2K (+100.0%) | 69.8K +69.8K (+100.0%) | 0.07% +0.070 pp | 0.00% +0.000 pp | USD3.14 +0.0% | 6 qtrs — |
| 48 | VANGUARD PERSONALIZED INDEXING MANAGEMENT, LLC | 19.8K -318.0 (-1.6%) | 62.3K -15.3K (-19.7%) | 0.06% -0.010 pp | 0.00% 0.000 pp | USD2.52 +24.6% | 5 qtrs — |
| 49 | LIGHTHOUSE INVESTMENT PARTNERS, LLC | 18.7K +18.7K (+100.0%) | 58.8K +58.8K (+100.0%) | 0.06% +0.059 pp | 0.00% +0.002 pp | USD3.14 +0.0% | 1 qtrs NEW |
| 50 | HSBC HOLDINGS PLC | 17.1K +— (+0.0%) | 54.2K -10.1K (-15.6%) | 0.05% -0.007 pp | 0.00% +0.000 pp | USD3.85 -18.4% | 2 qtrs — |
| 51 | QUADRATURE CAPITAL LTD | 17.1K +17.1K (+100.0%) | 53.8K +53.8K (+100.0%) | 0.05% +0.054 pp | 0.00% +0.001 pp | USD3.14 +0.0% | 1 qtrs NEW |
| 52 | BANK OF MONTREAL /CAN/ | 16.2K +2.0 (+0.0%) | 50.9K -11.5K (-18.4%) | 0.05% -0.007 pp | 0.00% +0.000 pp | USD4.57 -31.3% | 5 qtrs — |
| 53 | SHERBROOKE PARK ADVISERS LLC | 15.4K -1.2K (-7.0%) | 48.3K -15.4K (-24.2%) | 0.05% -0.011 pp | 0.12% +0.095 pp | USD3.85 -18.4% | 2 qtrs — |
| 54 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 15.1K -5.0 (0.0%) | 47.3K -10.7K (-18.5%) | 0.05% -0.006 pp | 0.00% +0.000 pp | USD12.94 -75.7% | 7 qtrs — |
| 55 | PRELUDE CAPITAL MANAGEMENT, LLC | 14.5K +14.5K (+100.0%) | 45.5K +45.5K (+100.0%) | 0.05% +0.046 pp | 0.00% +0.003 pp | USD3.14 +0.0% | 1 qtrs NEW |
| 56 | — | 14.1K +14.1K (+100.0%) | 44.4K +44.4K (+100.0%) | 0.04% +0.044 pp | 0.04% +0.044 pp | USD3.14 +0.0% | 1 qtrs NEW |
| 57 | BANK OF AMERICA CORP /DE/ | 13.2K -356.1K (-96.4%) | 41.6K -1.4M (-97.1%) | 0.04% -1.272 pp | 0.00% 0.000 pp | USD4.49 -30.1% | 7 qtrs — |
| 58 | R SQUARED LTD | 13.1K +13.1K (+100.0%) | 41.2K +41.2K (+100.0%) | 0.04% +0.041 pp | 0.02% +0.019 pp | USD3.14 +0.0% | 1 qtrs NEW |
| 59 | POST RESCH TALLON GROUP INC. | 12.8K -7.3K (-36.3%) | 40.0K -37.0K (-48.0%) | 0.04% -0.031 pp | 0.03% -0.034 pp | USD3.85 -18.4% | 2 qtrs — |
| 60 | AQR CAPITAL MANAGEMENT LLC | 11.6K -15.7K (-57.6%) | 36.3K -68.7K (-65.4%) | 0.04% -0.061 pp | 0.00% +0.000 pp | USD1.99 +57.8% | 7 qtrs — |
| 61 | VALUES FIRST ADVISORS, INC. | 11.1K -2.3K (-17.0%) | 34.7K -16.6K (-32.3%) | 0.03% -0.013 pp | 0.02% -0.010 pp | USD15.98 -80.4% | 7 qtrs — |
| 62 | NEWEDGE ADVISORS, LLC | 10.6K -33.9K (-76.2%) | 33.3K -137.8K (-80.6%) | 0.03% -0.125 pp | 0.00% -0.001 pp | USD3.85 -18.4% | 2 qtrs — |
| 63 | WELLS FARGO & COMPANY/MN | 10.2K -3.1K (-23.5%) | 32.0K -19.3K (-37.7%) | 0.03% -0.015 pp | 0.00% +0.000 pp | USD13.29 -76.4% | 7 qtrs — |
| 64 | MSA ADVISORS, LLC | 10.0K +— (+0.0%) | 31.4K -7.1K (-18.4%) | 0.03% -0.004 pp | 0.01% -0.002 pp | USD4.57 -31.3% | 3 qtrs — |
| 65 | TOWER RESEARCH CAPITAL LLC (TRC) | 8.4K +2.9K (+51.5%) | 26.4K +5.0K (+23.6%) | 0.03% +0.007 pp | 0.00% +0.000 pp | USD5.41 -42.0% | 7 qtrs — |
| 66 | FMR LLC | 5.4K -264.0 (-4.6%) | 17.0K -4.9K (-22.2%) | 0.02% -0.003 pp | 0.00% +0.000 pp | USD12.38 -74.6% | 7 qtrs — |
| 67 | FIRST COMMAND ADVISORY SERVICES, INC. | 3.5K +— (+0.0%) | 11.1K -2.5K (-18.4%) | 0.01% -0.002 pp | 0.00% +0.000 pp | USD5.48 -42.7% | 6 qtrs — |
| 68 | PINNACLE WEALTH PLANNING SERVICES, INC. | 3.4K +3.4K (+100.0%) | 10.6K +10.6K (+100.0%) | 0.01% +0.011 pp | 0.00% +0.001 pp | USD3.14 +0.0% | 1 qtrs NEW |
| 69 | ROYAL BANK OF CANADA | 2.1K -10.7K (-83.4%) | 7.0K -42.0K (-85.7%) | 0.01% -0.039 pp | 0.00% +0.000 pp | USD4.91 -36.0% | 7 qtrs — |
| 70 | CORECAP ADVISORS, LLC | 2.0K +— (+0.0%) | 6.3K -1.4K (-18.4%) | 0.01% -0.001 pp | 0.00% 0.000 pp | USD4.57 -31.3% | 3 qtrs — |
| 71 | CWM, LLC | 1.9K -3.0K (-61.4%) | 6.0K -13.0K (-68.4%) | 0.01% -0.012 pp | 0.00% +0.000 pp | USD3.15 -0.3% | 5 qtrs — |
| 72 | OPTIVER HOLDING B.V. | 1.4K +1.4K (+6,765.0%) | 4.3K +4.2K (+5,498.7%) | 0.00% +0.004 pp | 0.00% +0.000 pp | USD3.15 -0.3% | 2 qtrs — |
| 73 | CHILTON CAPITAL MANAGEMENT LLC | 1.1K +— (+0.0%) | 3.3K -751.0 (-18.4%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD16.69 -81.2% | 7 qtrs — |
| 74 | COVESTOR LTD | 1.0K +— (+0.0%) | 3.0K -1.0K (-25.0%) | 0.00% 0.000 pp | 0.00% -0.001 pp | USD5.48 -42.7% | 6 qtrs — |
| 75 | NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO | 633.00 -75.0 (-10.6%) | 2.0K -738.0 (-27.1%) | 0.00% -0.001 pp | 0.00% +0.000 pp | USD14.95 -79.0% | 7 qtrs — |
| 76 | PHYSICIAN WEALTH ADVISORS, INC. | 621.00 +— (+0.0%) | 2.0K -441.0 (-18.4%) | 0.00% 0.000 pp | 0.00% 0.000 pp | USD1.51 +107.9% | 4 qtrs — |
| 77 | GAME PLAN FINANCIAL ADVISORS, LLC | 585.00 +— (+0.0%) | 1.8K -415.0 (-18.4%) | 0.00% 0.000 pp | 0.00% 0.000 pp | USD1.51 +107.9% | 7 qtrs — |
| 78 | RHUMBLINE ADVISERS | 538.00 +— (+0.0%) | 1.7K -382.0 (-18.4%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD16.69 -81.2% | 7 qtrs — |
| 79 | HUNTINGTON NATIONAL BANK | 500.00 +— (+0.0%) | 1.6K -355.0 (-18.4%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD1.51 +107.9% | 4 qtrs — |
| 80 | RUSSELL INVESTMENTS GROUP, LTD. | 433.00 -2.8K (-86.5%) | 1.4K -11.0K (-89.0%) | 0.00% -0.010 pp | 0.00% +0.000 pp | USD4.48 -29.9% | 7 qtrs — |
| 81 | NISA INVESTMENT ADVISORS, LLC | 410.00 +— (+0.0%) | 1.3K -292.0 (-18.5%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD4.57 -31.3% | 7 qtrs — |
| 82 | JPMORGAN CHASE & CO | 382.00 -28.7K (-98.7%) | 1.2K -110.8K (-98.9%) | 0.00% -0.102 pp | 0.00% +0.000 pp | USD5.84 -46.2% | 7 qtrs — |
| 83 | JONES FINANCIAL COMPANIES LLLP | 371.00 +— (+0.0%) | 1.2K -300.0 (-20.5%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD2.76 +13.8% | 5 qtrs — |
| 84 | RIALTO WEALTH MANAGEMENT, LLC | 305.00 +— (+0.0%) | 958.00 -217.0 (-18.5%) | 0.00% 0.000 pp | 0.00% 0.000 pp | USD1.51 +107.9% | 4 qtrs — |
| 85 | FORTITUDE FAMILY OFFICE, LLC | 296.00 +— (+0.0%) | 929.00 -211.0 (-18.5%) | 0.00% 0.000 pp | 0.00% 0.000 pp | USD4.57 -31.3% | 3 qtrs — |
| 86 | EVERSOURCE WEALTH ADVISORS, LLC | 274.00 +— (+0.0%) | 860.00 -195.0 (-18.5%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD4.04 -22.3% | 7 qtrs — |
| 87 | ATLANTIC UNION BANKSHARES CORP | 250.00 +— (+0.0%) | 785.00 -178.0 (-18.5%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD4.57 -31.3% | 3 qtrs — |
| 88 | FEDERATION DES CAISSES DESJARDINS DU QUEBEC | 100.00 +— (+0.0%) | 314.00 -71.0 (-18.4%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD16.69 -81.2% | 7 qtrs — |
| 89 | BNP PARIBAS ARBITRAGE, SNC | 96.00 +19.0 (+24.7%) | 301.00 +5.0 (+1.7%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD5.39 -41.7% | 7 qtrs — |
| 90 | ALLWORTH FINANCIAL LP | 58.00 +50.0 (+625.0%) | 183.00 +152.0 (+490.3%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD3.50 -10.3% | 7 qtrs — |
| 91 | ROOT FINANCIAL PARTNERS, LLC | 25.00 +— (+0.0%) | 79.00 -17.0 (-17.7%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD3.84 -18.2% | 2 qtrs — |
| 92 | IFP ADVISORS, INC | 15.00 -1.0 (-6.3%) | 47.00 -15.0 (-24.2%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD3.80 -17.4% | 2 qtrs — |
| 93 | HORIZON FINANCIAL SERVICES, LLC | 9.00 +9.0 (+100.0%) | 28.00 +28.0 (+100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD3.11 +1.0% | 1 qtrs NEW |
| 94 | PARALLEL ADVISORS, LLC | 5.00 -19.0 (-79.2%) | 16.00 -76.0 (-82.6%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD4.40 -28.6% | 3 qtrs — |
| 95 | SBI SECURITIES CO., LTD. | 5.00 -301.0 (-98.4%) | 16.00 -1.2K (-98.6%) | 0.00% -0.001 pp | 0.00% +0.000 pp | USD3.80 -17.4% | 5 qtrs — |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 35 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Invesco NASDAQ Future Gen 200 ETF QQQS | 0.48% | 105.0K | 0.20% |
| 2 | iShares Micro-Cap ETF IWC | 0.03% | 448.8K | 0.60% |
| 3 | iShares Russell 2000 Value ETF IWN | 0.01% | 813.7K | 0.24% |
| 4 | Global X - Russell 2000 ETF RSSL | 0.00% | 62.4K | 0.08% |
| 5 | Invesco Russell 2000 UCITS ETF RTYS.L | 0.00% | 13.5K | 0.25% |
| 6 | Xtrackers Russell 2000 UCITS ETF 1C XRSU.L | 0.00% | 114.0K | 0.30% |
| 7 | iShares Russell 2000 BuyWrite ETF IWMW | 0.00% | 2.1K | 0.39% |
| 8 | iShares Russell 2000 ETF IWM | 0.00% | 3.09M | 0.19% |
| 9 | iShares U.S. Small Cap Index ETF (CAD-Hedged) XSU.TO | 0.00% | 20.2K | 0.36% |
| 10 | iShares Russell 2000 Growth ETF IWO | 0.00% | 552.0K | 0.24% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
1
Sells
0
Shares acquired
2.4K
Shares disposed
—
Cash buys
—
Cash sales
—
Net activity
+2,448
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-05-01 | ARMEN GARO H | Director / Officer | A-Award | A | Common Stock | 4,233 | 3.84 | 16.3K | 346,783 | D | ↗ |
| 2026-04-24 | Wright Timothy | Director | A-Award | A | Stock Option | 105,000 | 3.90 | 409.5K | 105,000 | D | ↗ |
| 2026-04-24 | O'Day Steven J | Officer | A-Award | A | Stock Option | 70,000 | 3.90 | 273.0K | 70,000 | D | ↗ |
| 2026-04-24 | Hirsch Susan B | Director | A-Award | A | Stock Option | 105,000 | 3.90 | 409.5K | 105,000 | D | ↗ |
| 2026-04-24 | HARRISON THOMAS L | Director | A-Award | A | Stock Option | 122,500 | 3.90 | 477.8K | 122,500 | D | ↗ |
| 2026-04-24 | Corvese Brian | Director | A-Award | A | Stock Option | 210,000 | 3.90 | 819.0K | 210,000 | D | ↗ |
| 2026-04-24 | Charette Austin | Officer | A-Award | A | Stock Option | 5,000 | 3.90 | 19.5K | 5,000 | D | ↗ |
| 2026-04-24 | Buell Jennifer | Director / Officer | A-Award | A | Stock Option | 5,000 | 3.90 | 19.5K | 5,000 | D | ↗ |
| 2026-04-24 | ARMEN GARO H | Director / Officer | A-Award | A | Stock Option | 27,750 | 3.90 | 108.2K | 27,750 | D | ↗ |
| 2026-04-17 | ARMEN GARO H | Director / Officer | A-Award | A | Common Stock | 3,403 | 4.79 | 16.3K | 342,550 | D | ↗ |
| 2026-04-03 | ARMEN GARO H | Director / Officer | A-Award | A | Common Stock | 4,629 | 3.33 | 15.4K | 339,147 | D | ↗ |
| 2026-04-01 | Wright Timothy | Director | A-Award | A | Deferred Stock Units | 2,448 | 0.00 | — | 26,361 | D | ↗ |
| 2026-04-01 | HARRISON THOMAS L | Director | A-Award | A | Common Stock | 9,228 | 3.32 | 30.6K | 38,998 | D | ↗ |
| 2026-03-20 | ARMEN GARO H | Director / Officer | A-Award | A | Common Stock | 3,983 | 3.71 | 14.8K | 334,518 | D | ↗ |
| 2026-03-06 | ARMEN GARO H | Director / Officer | A-Award | A | Common Stock | 4,994 | 2.96 | 14.8K | 330,535 | D | ↗ |
| 2026-02-20 | ARMEN GARO H | Director / Officer | A-Award | A | Common Stock | 4,829 | 3.06 | 14.8K | 325,541 | D | ↗ |
| 2026-02-06 | ARMEN GARO H | Director / Officer | A-Award | A | Common Stock | 5,027 | 2.94 | 14.8K | 320,712 | D | ↗ |
| 2026-01-23 | ARMEN GARO H | Director / Officer | A-Award | A | Common Stock | 4,562 | 3.24 | 14.8K | 315,685 | D | ↗ |
| 2026-01-09 | ARMEN GARO H | Director / Officer | A-Award | A | Common Stock | 3,780 | 3.91 | 14.8K | 311,123 | D | ↗ |
| 2026-01-08 | Charette Austin | Officer | — | — | Stock Option (Right to Buy) | 625 | 3.02 | 1.9K | 0 | D | ↗ |
| 2026-01-02 | Wright Timothy | Director | A-Award | A | Deferred Stock Units | 2,041 | 0.00 | — | 23,913 | D | ↗ |
| 2026-01-02 | HARRISON THOMAS L | Director | A-Award | A | Common Stock | 7,691 | 3.98 | 30.6K | 29,770 | D | ↗ |
| 2025-12-26 | ARMEN GARO H | Director / Officer | A-Award | A | Common Stock | 4,942 | 3.31 | 16.4K | 307,343 | D | ↗ |
| 2025-12-12 | ARMEN GARO H | Director / Officer | A-Award | A | Common Stock | 4,316 | 3.79 | 16.4K | 302,401 | D | ↗ |
| 2025-11-28 | ARMEN GARO H | Director / Officer | A-Award | A | Common Stock | 3,587 | 4.56 | 16.4K | 298,085 | D | ↗ |
| 2025-11-14 | ARMEN GARO H | Director / Officer | A-Award | A | Common Stock | 3,769 | 4.34 | 16.4K | 294,498 | D | ↗ |
| 2025-10-31 | ARMEN GARO H | Director / Officer | A-Award | A | Common Stock | 4,120 | 3.97 | 16.4K | 290,729 | D | ↗ |
| 2025-10-17 | ARMEN GARO H | Director / Officer | A-Award | A | Common Stock | 4,216 | 3.88 | 16.4K | 286,609 | D | ↗ |
| 2025-10-03 | ARMEN GARO H | Director / Officer | A-Award | A | Common Stock | 3,951 | 4.14 | 16.4K | 282,393 | D | ↗ |
| 2025-10-01 | Wright Timothy | Director | A-Award | A | Deferred Stock Units | 1,705 | 0.00 | — | 21,872 | D | ↗ |
| 2025-10-01 | HARRISON THOMAS L | Director | A-Award | A | Common Stock | 5,780 | 5.01 | 29.0K | 22,079 | D | ↗ |
| 2025-09-19 | ARMEN GARO H | Director / Officer | A-Award | A | Common Stock | 3,734 | 4.38 | 16.4K | 278,442 | D | ↗ |
| 2025-09-05 | ARMEN GARO H | Director / Officer | A-Award | A | Common Stock | 3,778 | 4.33 | 16.4K | 274,708 | D | ↗ |
| 2025-08-22 | ARMEN GARO H | Director / Officer | A-Award | A | Common Stock | 3,619 | 4.52 | 16.4K | 270,930 | D | ↗ |
| 2025-08-08 | ARMEN GARO H | Director / Officer | A-Award | A | Common Stock | 3,407 | 4.80 | 16.4K | 267,311 | D | ↗ |
| 2025-07-25 | ARMEN GARO H | Director / Officer | A-Award | A | Common Stock | 2,745 | 5.96 | 16.4K | 263,904 | D | ↗ |
| 2025-07-11 | ARMEN GARO H | Director / Officer | A-Award | A | Common Stock | 2,317 | 7.06 | 16.4K | 261,159 | D | ↗ |
| 2025-07-01 | Wright Timothy | Director | A-Award | A | Deferred Stock Units | 2,708 | 0.00 | — | 20,168 | D | ↗ |
| 2025-07-01 | HARRISON THOMAS L | Director | A-Award | A | Common Stock | 7,401 | 3.46 | 25.6K | 16,299 | D | ↗ |
| 2025-06-27 | ARMEN GARO H | Director / Officer | A-Award | A | Common Stock | 3,436 | 4.76 | 16.4K | 258,842 | D | ↗ |
| 2025-06-18 | O'Day Steven J | Officer | A-Award | A | Common Stock | 43,497 | 4.47 | 194.4K | 57,116 | D | ↗ |
| 2025-06-18 | KLASKIN CHRISTINE M | Officer | A-Award | A | Common Stock | 15,782 | 4.47 | 70.5K | 23,478 | D | ↗ |
| 2025-06-18 | ARMEN GARO H | Director / Officer | A-Award | A | Common Stock | 61,397 | 4.47 | 274.4K | 255,406 | D | ↗ |
| 2025-06-17 | Wright Timothy | Director | A-Award | A | Stock Option | 15,000 | 3.02 | 45.3K | 15,000 | D | ↗ |
| 2025-06-17 | KLASKIN CHRISTINE M | Officer | A-Award | A | Stock Option | 7,250 | 3.02 | 21.9K | 7,250 | D | ↗ |
| 2025-06-17 | Hirsch Susan B | Director | A-Award | A | Stock Option | 15,000 | 3.02 | 45.3K | 15,000 | D | ↗ |
| 2025-06-17 | HARRISON THOMAS L | Director | A-Award | A | Stock Option | 17,500 | 3.02 | 52.9K | 30,000 | D | ↗ |
| 2025-06-17 | Corvese Brian | Director | A-Award | A | Stock Option | 30,000 | 3.02 | 90.6K | 30,000 | D | ↗ |
| 2025-06-17 | ARMEN GARO H | Director / Officer | A-Award | A | Stock Option | 37,500 | 3.02 | 113.3K | 37,500 | D | ↗ |
| 2025-06-13 | ARMEN GARO H | Director / Officer | A-Award | A | Common Stock | 3,480 | 4.70 | 16.4K | 194,009 | D | ↗ |
| 2025-05-30 | ARMEN GARO H | Director / Officer | A-Award | A | Common Stock | 4,769 | 3.43 | 16.4K | 190,529 | D | ↗ |
| 2025-05-16 | ARMEN GARO H | Director / Officer | A-Award | A | Common Stock | 4,700 | 3.48 | 16.4K | 185,750 | D | ↗ |
| 2025-05-02 | Buell Jennifer | Director | A-Award | A | Common Stock | 581 | 3.11 | 1.8K | 19,738 | D | ↗ |
| 2025-05-02 | ARMEN GARO H | Director / Officer | A-Award | A | Common Stock | 5,260 | 3.11 | 16.4K | 181,060 | D | ↗ |
| 2025-04-18 | Buell Jennifer | Director | A-Award | A | Common Stock | 869 | 2.08 | 1.8K | 19,157 | D | ↗ |
| 2025-04-18 | ARMEN GARO H | Director / Officer | A-Award | A | Common Stock | 7,886 | 2.08 | 16.4K | 175,800 | D | ↗ |
| 2025-04-04 | Buell Jennifer | Director | A-Award | A | Common Stock | 1,159 | 1.56 | 1.8K | 18,288 | D | ↗ |
| 2025-04-04 | ARMEN GARO H | Director / Officer | A-Award | A | Common Stock | 10,288 | 1.56 | 16.0K | 167,914 | D | ↗ |
| 2025-04-01 | Wright Timothy | Director | A-Award | A | Deferred Stock Units | 3,256 | 0.00 | — | 17,460 | D | ↗ |
| 2025-04-01 | HARRISON THOMAS L | Director | A-Award | A | Common Stock | 8,898 | 2.88 | 25.6K | 8,898 | D | ↗ |
| 2025-03-21 | Buell Jennifer | Director | A-Award | A | Common Stock | 1,123 | 1.61 | 1.8K | 17,129 | D | ↗ |
| 2025-03-21 | ARMEN GARO H | Director / Officer | A-Award | A | Common Stock | 9,243 | 1.61 | 14.9K | 157,626 | D | ↗ |
| 2025-03-07 | Buell Jennifer | Director | A-Award | A | Common Stock | 409 | 2.35 | 961.15 | 15,646 | D | ↗ |
| 2025-03-07 | ARMEN GARO H | Director / Officer | A-Award | A | Common Stock | 6,332 | 2.35 | 14.9K | 148,383 | D | ↗ |
| 2025-02-21 | Buell Jennifer | Director | A-Award | A | Common Stock | 545 | 3.32 | 1.8K | 15,237 | D | ↗ |
| 2025-02-21 | ARMEN GARO H | Director / Officer | A-Award | A | Common Stock | 4,483 | 3.32 | 14.9K | 142,051 | D | ↗ |
| 2025-02-07 | Buell Jennifer | Director | A-Award | A | Common Stock | 516 | 3.50 | 1.8K | 14,692 | D | ↗ |
| 2025-02-07 | ARMEN GARO H | Director / Officer | A-Award | A | Common Stock | 4,251 | 3.50 | 14.9K | 137,568 | D | ↗ |
| 2025-01-24 | Buell Jennifer | Director | A-Award | A | Common Stock | 776 | 3.57 | 2.8K | 14,446 | D | ↗ |
| 2025-01-24 | ARMEN GARO H | Director / Officer | A-Award | A | Common Stock | 4,169 | 3.57 | 14.9K | 133,317 | D | ↗ |
| 2025-01-16 | Charette Austin | Officer | — | — | Stock Option (Right to Buy) | 625 | 12.26 | 7.7K | 0 | D | ↗ |
| 2025-01-10 | ARMEN GARO H | Director / Officer | A-Award | A | Common Stock | 4,777 | 3.12 | 14.9K | 129,148 | D | ↗ |
| 2025-01-02 | Wright Timothy | Director | A-Award | A | Deferred Stock Units | 2,533 | 0.00 | — | 14,204 | D | ↗ |
| 2025-01-01 | Hirsch Susan B | Director | A-Award | A | Deferred Stock Units | 6,416 | 0.00 | — | 16,207 | D | ↗ |
| 2024-12-27 | ARMEN GARO H | Director / Officer | A-Award | A | Common Stock | 5,931 | 2.75 | 16.3K | 124,371 | D | ↗ |
| 2024-12-13 | ARMEN GARO H | Director / Officer | A-Award | A | Common Stock | 5,347 | 3.05 | 16.3K | 118,440 | D | ↗ |
| 2024-11-29 | ARMEN GARO H | Director / Officer | A-Award | A | Common Stock | 4,769 | 3.42 | 16.3K | 113,093 | D | ↗ |
| 2024-11-15 | ARMEN GARO H | Director / Officer | A-Award | A | Common Stock | 5,997 | 2.72 | 16.3K | 108,324 | D | ↗ |
| 2024-11-14 | O'Day Steven J | Officer | A-Award | A | Stock Option | 50,000 | 2.77 | 138.5K | 50,000 | D | ↗ |
| 2024-11-14 | KLASKIN CHRISTINE M | Officer | A-Award | A | Stock Option | 10,000 | 2.77 | 27.7K | 10,000 | D | ↗ |
| 2024-11-14 | Buell Jennifer | Director / Officer | A-Award | A | Stock Option | 300,000 | 2.77 | 831.0K | 300,000 | D | ↗ |
| 2024-11-14 | ARMEN GARO H | Director / Officer | A-Award | A | Stock Option | 600,000 | 2.77 | 1.66M | 600,000 | D | ↗ |
| 2024-11-01 | ARMEN GARO H | Director / Officer | A-Award | A | Common Stock | 4,207 | 4.05 | 17.0K | 102,327 | D | ↗ |
| 2024-10-18 | ARMEN GARO H | Director / Officer | A-Award | A | Common Stock | 3,530 | 4.62 | 16.3K | 98,300 | D | ↗ |
| 2024-10-01 | Wright Timothy | Director | A-Award | A | Deferred Stock Units | 1,252 | 0.00 | — | 11,671 | D | ↗ |
| 2024-10-01 | WIINBERG ULF | Director | A-Award | A | Deferred Stock Units | 3,423 | 0.00 | — | 19,501 | D | ↗ |
| 2024-10-01 | Hirsch Susan B | Director | A-Award | A | Deferred Stock Units | 3,173 | 0.00 | — | 9,790 | D | ↗ |
| 2024-09-20 | ARMEN GARO H | Director / Officer | A-Award | A | Common Stock | 2,793 | 5.84 | 16.3K | 91,421 | D | ↗ |
| 2024-09-06 | ARMEN GARO H | Director / Officer | A-Award | A | Common Stock | 3,295 | 4.95 | 16.3K | 88,628 | — | ↗ |
| 2024-08-23 | ARMEN GARO H | Director / Officer | A-Award | A | Common Stock | 2,982 | 5.47 | 16.3K | 85,333 | — | ↗ |
| 2024-08-09 | ARMEN GARO H | Director / Officer | A-Award | A | Common Stock | 3,204 | 5.09 | 16.3K | 82,351 | — | ↗ |
| 2024-08-07 | HARRISON THOMAS L | Director | A-Award | A | Stock Option | 7,500 | 5.08 | 38.1K | 7,500 | — | ↗ |
| 2024-07-26 | ARMEN GARO H | Director / Officer | A-Award | A | Common Stock | 2,486 | 6.56 | 16.3K | 79,147 | — | ↗ |
| 2024-07-12 | ARMEN GARO H | Director / Officer | A-Award | A | Common Stock | 1,046 | 15.60 | 16.3K | 76,661 | — | ↗ |
| 2024-07-01 | Wright Timothy | Director | A-Award | A | Deferred Stock Units | 776 | 0.00 | — | 10,419 | — | ↗ |
| 2024-07-01 | WIINBERG ULF | Director | A-Award | A | Deferred Stock Units | 2,121 | 0.00 | — | 16,077 | — | ↗ |
| 2024-07-01 | Hirsch Susan B | Director | A-Award | A | Deferred Stock Units | 1,828 | 0.00 | — | 6,618 | — | ↗ |
| 2024-06-28 | ARMEN GARO H | Director / Officer | A-Award | A | Common Stock | 973 | 16.75 | 16.3K | 75,615 | — | ↗ |
| 2024-06-14 | ARMEN GARO H | Director / Officer | A-Award | A | Common Stock | 1,055 | 15.46 | 16.3K | 74,642 | — | ↗ |
| 2024-06-11 | Wright Timothy | Director | A-Award | A | Stock Option | 750 | 13.25 | 9.9K | 750 | — | ↗ |
| 2024-06-11 | O'Day Steven J | Officer | A-Award | A | Stock Option | 37,907 | 12.26 | 464.7K | 37,907 | — | ↗ |
| 2024-06-11 | KLASKIN CHRISTINE M | Officer | A-Award | A | Stock Option | 10,642 | 12.26 | 130.5K | 10,642 | — | ↗ |
| 2024-06-11 | Corvese Brian | Director | A-Award | A | Stock Option | 750 | 13.25 | 9.9K | 750 | — | ↗ |
| 2024-06-11 | Buell Jennifer | Director / Officer | — | D | Common Stock | 0 | 0.00 | — | 13,670 | — | ↗ |
| 2024-06-11 | ARMEN GARO H | Director / Officer | A-Award | A | Stock Option | 108,000 | 11.90 | 1.29M | 108,000 | — | ↗ |
| 2024-05-31 | ARMEN GARO H | Director / Officer | A-Award | A | Common Stock | 1,040 | 15.69 | 16.3K | 73,587 | — | ↗ |
| 2024-05-17 | ARMEN GARO H | Director / Officer | A-Award | A | Common Stock | 1,502 | 10.86 | 16.3K | 72,547 | — | ↗ |
| 2024-05-03 | ARMEN GARO H | Director / Officer | A-Award | A | Common Stock | 1,248 | 13.07 | 16.3K | 71,045 | — | ↗ |
| 2024-04-19 | ARMEN GARO H | Director / Officer | A-Award | A | Common Stock | 3,080 | 5.31 | 16.4K | 69,797 | — | ↗ |
| 2024-04-05 | ARMEN GARO H | Director / Officer | A-Award | A | Common Stock | 32,697 | 0.50 | 16.3K | 1,335,325 | — | ↗ |
| 2024-04-01 | Wright Timothy | Director | A-Award | A | Deferred Stock Units | 14,135 | 0.00 | — | 192,858 | — | ↗ |
| 2024-04-01 | WIINBERG ULF | Director | A-Award | A | Deferred Stock Units | 38,635 | 0.00 | — | 279,121 | — | ↗ |
| 2024-04-01 | Hirsch Susan B | Director | A-Award | A | Deferred Stock Units | 32,039 | 0.00 | — | 95,791 | — | ↗ |
| 2024-03-22 | ARMEN GARO H | Director / Officer | A-Award | A | Common Stock | 27,163 | 0.55 | 14.9K | 1,302,628 | — | ↗ |
| 2024-03-08 | ARMEN GARO H | Director / Officer | A-Award | A | Common Stock | 22,136 | 0.67 | 14.8K | 1,275,465 | — | ↗ |
| 2024-02-23 | ARMEN GARO H | Director / Officer | A-Award | A | Common Stock | 21,815 | 0.68 | 14.8K | 1,253,329 | — | ↗ |
| 2024-02-15 | ARMEN GARO H | Director / Officer | P-Purchase | A | Common Stock | 500,000 | 0.65 | 324.1K | 625,969 | — | ↗ |
| 2024-02-09 | ARMEN GARO H | Director / Officer | A-Award | A | Common Stock | 19,778 | 0.75 | 14.8K | 1,231,514 | — | ↗ |
| 2024-02-05 | Wright Timothy | Director | A-Award | A | Stock Option | 7,500 | 12.60 | 94.5K | 7,500 | — | ↗ |
| 2024-02-05 | WIINBERG ULF | Director | A-Award | A | Stock Option | 5,000 | 12.60 | 63.0K | 5,000 | — | ↗ |
| 2024-02-05 | Jeynes-Ellis Allison M | Director | A-Award | A | Stock Option | 5,000 | 12.60 | 63.0K | 5,000 | — | ↗ |
| 2024-02-05 | Hirsch Susan B | Director | A-Award | A | Stock Option | 5,000 | 12.60 | 63.0K | 5,000 | — | ↗ |
| 2024-02-05 | Corvese Brian | Director | A-Award | A | Stock Option | 15,000 | 12.60 | 189.0K | 15,000 | — | ↗ |
| 2024-01-26 | ARMEN GARO H | Director / Officer | A-Award | A | Common Stock | 22,475 | 0.66 | 14.8K | 1,211,736 | — | ↗ |
| 2024-01-12 | ARMEN GARO H | Director / Officer | A-Award | A | Common Stock | 23,177 | 0.64 | 14.8K | 1,439,261 | — | ↗ |
| 2024-01-05 | Charette Austin | Officer | — | — | Stock Option (Right to Buy) | 375 | 49.00 | 18.4K | 0 | D | ↗ |
| 2024-01-02 | Wright Timothy | Director | A-Award | A | Deferred Stock Units | 11,326 | 0.00 | — | 178,723 | — | ↗ |
| 2024-01-02 | WIINBERG ULF | Director | A-Award | A | Deferred Stock Units | 30,956 | 0.00 | — | 240,486 | — | ↗ |
| 2024-01-02 | Hirsch Susan B | Director | A-Award | A | Deferred Stock Units | 25,671 | 0.00 | — | 63,752 | — | ↗ |
| 2023-12-31 | Wright Timothy | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-12-31 | Hirsch Susan B | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-12-29 | ARMEN GARO H | Director / Officer | A-Award | A | Common Stock | 23,453 | 0.83 | 19.5K | 1,416,084 | — | ↗ |
| 2023-12-15 | ARMEN GARO H | Director / Officer | A-Award | A | Common Stock | 23,453 | 0.69 | 16.2K | 1,396,538 | — | ↗ |
| 2023-12-01 | ARMEN GARO H | Director / Officer | A-Award | A | Common Stock | 20,727 | 0.78 | 16.2K | 1,373,085 | — | ↗ |
| 2023-11-17 | ARMEN GARO H | Director / Officer | A-Award | A | Common Stock | 23,511 | 0.69 | 16.2K | 1,352,358 | — | ↗ |
| 2023-11-15 | WIINBERG ULF | Director | P-Purchase | A | Common Stock | 25,000 | 0.76 | 19.0K | 124,063 | — | ↗ |
| 2023-11-03 | ARMEN GARO H | Director / Officer | A-Award | A | Common Stock | 19,200 | 0.84 | 16.1K | 1,328,847 | — | ↗ |
| 2023-10-20 | ARMEN GARO H | Director / Officer | A-Award | A | Common Stock | 18,142 | 0.89 | 16.1K | 1,309,647 | — | ↗ |
| 2023-10-06 | ARMEN GARO H | Director / Officer | A-Award | A | Common Stock | 15,305 | 1.06 | 16.2K | 1,291,505 | — | ↗ |
| 2023-10-02 | Wright Timothy | Director | A-Award | A | Deferred Stock Units | 6,586 | 0.00 | — | 167,398 | — | ↗ |
| 2023-10-02 | WIINBERG ULF | Director | A-Award | A | Deferred Stock Units | 18,001 | 0.00 | — | 209,530 | — | ↗ |
| 2023-10-02 | Hirsch Susan B | Director | A-Award | A | Deferred Stock Units | 14,928 | 0.00 | — | 38,081 | — | ↗ |
| 2023-10-02 | HARRISON THOMAS L | Director | — | D | Stock Option | 1,250 | 21.00 | 26.3K | 0 | — | ↗ |
| 2023-09-22 | ARMEN GARO H | Director / Officer | A-Award | A | Common Stock | 13,888 | 1.18 | 16.4K | 1,276,200 | — | ↗ |
| 2023-09-08 | ARMEN GARO H | Director / Officer | A-Award | A | Common Stock | 13,145 | 1.23 | 16.2K | 1,262,312 | — | ↗ |
| 2023-07-03 | Wright Timothy | Director | A-Award | A | Deferred Stock Units | 5,860 | 0.00 | — | 160,812 | — | ↗ |
| 2023-07-03 | WIINBERG ULF | Director | A-Award | A | Deferred Stock Units | 16,018 | 0.00 | — | 191,528 | — | ↗ |
| 2023-07-03 | Hirsch Susan B | Director | A-Award | A | Deferred Stock Units | 13,283 | 0.00 | — | 23,153 | — | ↗ |
| 2023-04-03 | Wright Timothy | Director | A-Award | A | Deferred Stock Units | 4,354 | 0.00 | — | 154,952 | — | ↗ |
| 2023-04-03 | WIINBERG ULF | Director | A-Award | A | Deferred Stock Units | 11,902 | 0.00 | — | 175,510 | — | ↗ |
| 2023-04-03 | Hirsch Susan B | Director | A-Award | A | Deferred Stock Units | 9,870 | 0.00 | — | 9,870 | — | ↗ |
| 2023-01-09 | Buell Jennifer | Director / Officer | — | D | Stock Option, right to buy | 37,500 | 47.40 | 1.78M | 0 | — | ↗ |
| 2023-01-08 | Wright Timothy | Director | A-Award | A | Stock Option | 150,000 | 0.00 | — | 150,000 | — | ↗ |
| 2023-01-08 | WIINBERG ULF | Director | A-Award | A | Stock Option | 100,000 | 0.00 | — | 100,000 | — | ↗ |
| 2023-01-08 | Jeynes-Ellis Allison M | Director | A-Award | A | Stock Option | 100,000 | 0.00 | — | 100,000 | — | ↗ |
| 2023-01-08 | Hirsch Susan B | Director | A-Award | A | Stock Option | 100,000 | 0.00 | — | 100,000 | — | ↗ |
| 2023-01-05 | O'Day Steven J | Officer | A-Award | A | Common Stock | 109,381 | 2.45 | 268.0K | 272,384 | — | ↗ |
| 2023-01-05 | KLASKIN CHRISTINE M | Officer | A-Award | A | Common Stock | 31,294 | 2.45 | 76.7K | 153,937 | — | ↗ |
| 2023-01-05 | ARMEN GARO H | Officer | A-Award | A | Stock Option | 2,400,000 | 0.00 | — | 2,400,000 | — | ↗ |
| 2023-01-03 | Wright Timothy | Director | A-Award | A | Deferred Stock Units | 3,620 | 0.00 | — | 150,597 | — | ↗ |
| 2023-01-03 | WIINBERG ULF | Director | A-Award | A | Deferred Stock Units | 9,894 | 0.00 | — | 163,608 | — | ↗ |
| 2023-01-03 | Hirsch Susan B | Director | A-Award | A | Common Stock | 7,239 | 2.59 | 18.7K | 108,725 | — | ↗ |
| 2023-01-02 | Charette Austin | Officer | — | — | Stock Option (Right to Buy) | 375 | 64.40 | 24.2K | 0 | D | ↗ |
| 2023-01-01 | Charette Austin | Officer | — | — | Stock Option (Right to Buy) | 375 | 63.60 | 23.9K | 0 | D | ↗ |
| 2022-10-03 | Wright Timothy | Director | A-Award | A | Deferred Stock Units | 3,608 | 0.00 | — | 146,978 | — | ↗ |
| 2022-10-03 | WIINBERG ULF | Director | A-Award | A | Deferred Stock Units | 9,862 | 0.00 | — | 153,715 | — | ↗ |
| 2022-10-03 | JORDAN WADIH | Director | A-Award | A | Deferred Stock Units | 10,103 | 0.00 | — | 239,945 | — | ↗ |
| 2022-10-03 | Hirsch Susan B | Director | A-Award | A | Common Stock | 7,216 | 2.60 | 18.7K | 101,486 | — | ↗ |
| 2022-07-01 | Wright Timothy | Director | A-Award | A | Deferred Stock Units | 5,069 | 0.00 | — | 143,370 | — | ↗ |
| 2022-07-01 | WIINBERG ULF | Director | A-Award | A | Deferred Stock Units | 13,855 | 0.00 | — | 143,852 | — | ↗ |
| 2022-07-01 | JORDAN WADIH | Director | A-Award | A | Deferred Stock Units | 14,193 | 0.00 | — | 229,842 | — | ↗ |
| 2022-07-01 | Hirsch Susan B | Director | A-Award | A | Common Stock | 10,138 | 1.85 | 18.8K | 94,270 | — | ↗ |
| 2022-04-01 | Wright Timothy | Director | A-Award | A | Deferred Stock Units | 3,405 | 0.00 | — | 138,301 | — | ↗ |
| 2022-04-01 | WIINBERG ULF | Director | A-Award | A | Deferred Stock Units | 9,308 | 0.00 | — | 129,997 | — | ↗ |
| 2022-04-01 | JORDAN WADIH | Director | A-Award | A | Deferred Stock Units | 9,535 | 0.00 | — | 215,649 | — | ↗ |
| 2022-04-01 | Hirsch Susan B | Director | A-Award | A | Common Stock | 6,811 | 2.75 | 18.8K | 28,382 | — | ↗ |
| 2022-02-04 | Wright Timothy | Director | A-Award | A | Stock Option (Right to Buy) | 150,000 | 2.39 | 358.5K | 150,000 | — | ↗ |
| 2022-02-04 | WIINBERG ULF | Director | A-Award | A | Stock Option (Right to Buy) | 100,000 | 2.39 | 239.0K | 100,000 | — | ↗ |
| 2022-02-04 | Jeynes-Ellis Allison M | Director | A-Award | A | Stock Option (Right to Buy) | 100,000 | 2.39 | 239.0K | 100,000 | — | ↗ |
| 2022-02-04 | JORDAN WADIH | Director | A-Award | A | Stock Option (Right to Buy) | 100,000 | 2.39 | 239.0K | 100,000 | — | ↗ |
| 2022-02-04 | Hirsch Susan B | Director | A-Award | A | Stock Option (Right to Buy) | 100,000 | 2.39 | 239.0K | 100,000 | — | ↗ |
| 2022-02-04 | Corvese Brian | Director | A-Award | A | Stock Option (Right to Buy) | 150,000 | 2.39 | 358.5K | 150,000 | — | ↗ |
| 2022-02-02 | O'Day Steven J | Officer | A-Award | A | Common Stock | 101,682 | 2.51 | 255.2K | 163,003 | — | ↗ |
| 2022-02-02 | KLASKIN CHRISTINE M | Officer | A-Award | A | Common Stock | 29,587 | 2.51 | 74.3K | 122,643 | — | ↗ |
| 2022-02-02 | ARMEN GARO H | Director / Officer | A-Award | A | Common Stock | 237,011 | 2.51 | 594.9K | 1,007,784 | — | ↗ |
| 2022-01-06 | O'Day Steven J | Officer | S-Sale | D | Common Stock | 38,679 | 3.06 | 118.3K | 61,321 | — | ↗ |
| 2022-01-04 | O'Day Steven J | Officer | M-Exempt | A | Common Stock | 100,000 | 0.00 | — | 100,000 | — | ↗ |
| 2022-01-03 | Wright Timothy | Director | A-Award | A | Deferred Stock Units | 2,339 | 0.00 | — | 134,895 | — | ↗ |
| 2022-01-03 | WIINBERG ULF | Director | A-Award | A | Deferred Stock Units | 6,392 | 0.00 | — | 120,690 | — | ↗ |
| 2022-01-03 | JORDAN WADIH | Director | A-Award | A | Deferred Stock Units | 6,548 | 0.00 | — | 206,114 | — | ↗ |
| 2022-01-03 | Hirsch Susan B | Director | A-Award | A | Common Stock | 4,677 | 4.01 | 18.8K | 21,571 | — | ↗ |
| 2022-01-02 | O'Day Steven J | Officer | A-Award | A | Stock Option (Right to Buy) | 150,000 | 3.22 | 483.0K | 150,000 | — | ↗ |
| 2022-01-02 | KLASKIN CHRISTINE M | Officer | A-Award | A | Stock Option (Right to Buy) | 100,000 | 3.22 | 322.0K | 100,000 | — | ↗ |
| 2022-01-02 | Buell Jennifer | Director / Officer | — | D | Stock Option, right to buy | 7,500 | 64.40 | 483.0K | 0 | — | ↗ |
| 2022-01-02 | ARMEN GARO H | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 1,900,000 | 3.22 | 6.12M | 1,900,000 | — | ↗ |
| 2021-12-17 | Charette Austin | Officer | — | — | Stock Option (Right to Buy) | 375 | 74.00 | 27.8K | 0 | D | ↗ |
| 2021-10-01 | Wright Timothy | Director | A-Award | A | Deferred Stock Units | 1,629 | 0.00 | — | 132,557 | — | ↗ |
| 2021-10-01 | WIINBERG ULF | Director | A-Award | A | Deferred Stock Units | 4,451 | 0.00 | — | 114,298 | — | ↗ |
| 2021-10-01 | JORDAN WADIH | Director | A-Award | A | Deferred Stock Units | 4,560 | 0.00 | — | 199,566 | — | ↗ |
| 2021-10-01 | Hirsch Susan B | Director | A-Award | A | Common Stock | 3,257 | 5.76 | 18.8K | 16,894 | — | ↗ |
Executive team
Top executives
EBIT / Employee
-65.1K
Shares Outstanding
38.40M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Garo H. Armen, Ph.D. Chief Executive Officer | 715.3K | 429.2K | — | 141.0K | — | 64.9K | 1.35M | 10.44% | ↗ |
| 2 | 2025 | Steven J. O’Day, M.D. Chief Medical Officer | 594.9K | 297.4K | — | — | — | 10.5K | 902.8K | 0.00% | ↗ |
| 3 | 2025 | Christine M. Klaskin Vice President, Finance | 298.2K | — | — | 27.3K | — | 6.5K | 332.0K | 8.21% | ↗ |
| 4 | 2024 | Garo H. Armen, Ph.D. Chief Executive Officer | 715.3K | 429.2K | — | 2.95M | — | 56.4K | 4.15M | 71.04% | ↗ |
| 5 | 2024 | Garo H. Armen, Ph.D. Chief Executive Officer | 715.3K | — | — | 2.95M | — | 56.4K | 3.72M | 79.24% | ↗ |
| 6 | 2024 | Steven J. O’Day, M.D. Chief Medical Officer | 594.9K | 297.4K | — | 363.3K | — | 10.4K | 1.27M | 28.70% | ↗ |
| 7 | 2024 | Steven J. O’Day, M.D. Chief Medical Officer | 594.9K | — | — | 363.3K | — | 10.4K | 968.5K | 37.51% | ↗ |
| 8 | 2024 | Christine M. Klaskin Vice President, Finance | 298.2K | 104.4K | — | 178.9K | — | 6.3K | 587.9K | 30.44% | ↗ |
| 9 | 2024 | Christine M. Klaskin Vice President, Finance | 298.2K | — | — | 178.9K | — | 6.3K | 483.5K | 37.01% | ↗ |
| 10 | 2023 | Garo H. Armen, Ph.D. Chief Executive Officer | 710.5K | 625.0K | 312.5K | 4.21M | — | — | 5.86M | 77.20% | ↗ |
| 11 | 2023 | Steven J. O’Day, M.D. Chief Medical Officer | 590.5K | 371.8K | 143.0K | 322.0K | — | 8.7K | 1.44M | 32.38% | ↗ |
| 12 | 2023 | Christine M. Klaskin Vice President, Finance | 296.2K | 104.4K | 43.0K | 262.3K | — | 6.8K | 712.7K | 42.84% | ↗ |
| 13 | 2022 | Garo H. Armen, Ph.D. Chief Executive Officer | 689.0K | 625.0K | 312.5K | 4.00M | — | — | 5.63M | 76.65% | ↗ |
| 14 | 2022 | Steven J. O’Day, M.D. Chief Medical Officer | 572.4K | 286.0K | 130.6K | 313.5K | — | 8.7K | 1.31M | 33.87% | ↗ |
| 15 | 2022 | Christine M. Klaskin Vice President, Finance | 287.2K | 86.0K | 39.3K | 209.0K | — | 6.6K | 628.1K | 39.53% | ↗ |
| 16 | 2021 | Garo H. Armen, Ph.D. Chief Executive Officer | 655.0K | 625.0K | 196.5K | 8.28M | — | 4.1K | 9.76M | 86.84% | ↗ |
| 17 | 2021 | Jennifer Buell, Ph.D. Former President and Chief Operating Officer | 480.0K | 432.4K | 2.22M | 4.28M | — | 4.9K | 7.42M | 87.63% | ↗ |
| 18 | 2021 | Steven J. O’Day, M.D. Chief Medical Officer | 539.4K | 891.3K | 323.0K | 610.4K | — | 8.7K | 2.37M | 39.34% | ↗ |
| 19 | 2021 | Steven J. O’Day, M.D. Chief Medical Officer | 539.4K | 891.3K | 323.0K | 610.4K | — | 8.7K | 2.37M | 39.34% | ↗ |
| 20 | 2021 | Adam Krauss Former Chief Legal Officer and Chief Compliance Officer | 242.8K | — | — | 624.1K | — | 8.5K | 875.4K | 71.29% | ↗ |
| 21 | 2021 | Christine M. Klaskin Vice President, Finance | 275.7K | 78.6K | 36.0K | 178.3K | — | 6.2K | 574.8K | 37.28% | ↗ |
| 22 | 2020 | Garo H. Armen, Ph.D. Chief Executive Officer | 677.3K | 393.0K | — | 4.56M | — | 3.8K | 5.64M | 80.95% | ↗ |
| 23 | 2020 | Jennifer Buell, Ph.D. President and Chief Operating Officer | 483.1K | 220.0K | — | 2.12M | — | 4.8K | 2.83M | 74.98% | ↗ |
| 24 | 2020 | Jennifer Buell, Ph.D. Former President and Chief Operating Officer | 483.1K | 220.0K | — | 2.12M | — | 4.8K | 2.83M | 74.98% | ↗ |
| 25 | 2020 | Evan D. Kearns Vice President and General Counsel | 407.7K | 160.0K | — | 350.0K | — | 5.7K | 923.4K | 37.90% | ↗ |
| 26 | 2020 | Christine M. Klaskin Vice President, Finance | 285.2K | 72.0K | — | 144.7K | — | 5.8K | 507.7K | 28.51% | ↗ |
| 27 | 2020 | Christine M. Klaskin Vice President, Finance | 285.2K | 72.0K | — | 144.7K | — | 5.8K | 507.7K | 28.51% | ↗ |
| 28 | 2020 | Adam Krauss Former Chief Legal Officer and Chief Compliance Officer | 33.8K | — | 129.5K | 291.3K | — | — | 454.7K | 92.56% | ↗ |
| 29 | 2020 | Adam Krauss Former Chief Legal Officer and Chief Compliance Officer | 33.8K | — | 129.5K | 291.3K | — | — | 454.7K | 92.56% | ↗ |
| 30 | 2019 | Garo H. Armen, Ph.D. Chief Executive Officer | 634.4K | 550.0K | 1.91M | — | — | 4.2K | 9.94M | 19.23% | ↗ |
| 31 | 2019 | Jennifer Buell, Ph.D. Former President and Chief Operating Officer | 407.6K | 275.0K | — | 1.70M | — | — | 2.39M | 71.18% | ↗ |
| 32 | 2019 | Jennifer Buell, Ph.D. President and Chief Operating Officer | 407.6K | 275.0K | — | 1.70M | — | — | 2.39M | 71.18% | ↗ |
| 33 | 2019 | Jennifer S. Buell, Ph.D. President and Chief Operating Officer | 407.6K | 275.0K | — | 1.70M | — | 4.9K | 2.39M | 71.18% | ↗ |
| 34 | 2019 | Evan D. Kearns Vice President and General Counsel | 353.3K | 230.0K | — | 1.02M | — | 5.8K | 1.61M | 63.43% | ↗ |
| 35 | 2019 | Evan D. Kearns Vice President and General Counsel | 353.3K | 230.0K | — | 1.02M | — | 5.8K | 1.61M | 63.43% | ↗ |
| 36 | 2018 | Garo H. Armen, Ph.D. Chief Executive Officer | 610.5K | 525.0K | 144.0K | — | — | 4.1K | 2.57M | 5.61% | ↗ |
| 37 | 2018 | Jennifer S. Buell, Ph.D. President and Chief Operating Officer | 340.7K | 250.0K | 13.5K | 377.6K | — | 4.7K | 986.5K | 39.64% | ↗ |
| 38 | 2018 | Jennifer Buell, Ph.D. President and Chief Operating Officer | 340.7K | 250.0K | 13.5K | 377.6K | — | 4.7K | 986.5K | 39.64% | ↗ |
| 39 | 2018 | Jennifer Buell, Ph.D. President and Chief Operating Officer | 340.7K | 250.0K | 13.5K | 377.6K | — | 4.7K | 986.5K | 39.64% | ↗ |
| 40 | 2018 | Alexander Duncan, Ph.D. Chief Technology Officer and Head of Research | 355.5K | 166.7K | 4.3K | 226.6K | — | 80.2K | 833.3K | 27.71% | ↗ |
| 41 | 2017 | Garo H. Armen, Ph.D. Chief Executive Officer | 592.8K | 486.0K | 1.06M | 1.61M | — | 18.0K | 3.77M | 70.91% | ↗ |
| 42 | 2017 | Robert Stein, Ph.D. Former President, RD | 122.6K | — | — | 320.0K | — | 600.4K | 1.04M | 30.68% | ↗ |
| 43 | 2017 | Jean-Marie Cuillerot, M.D. | 415.1K | — | — | 623.4K | — | — | 1.04M | 60.03% | ↗ |
| 44 | 2017 | Karen H. Valentine Chief Legal Officer and General Counsel | 347.1K | 210.0K | — | 307.1K | — | 6.0K | 870.2K | 35.29% | ↗ |
| 45 | 2017 | Alexander Duncan, Ph.D. Chief Technology Officer and Head of Research | 314.7K | 175.0K | — | 307.1K | — | 61.5K | 858.2K | 35.78% | ↗ |
| 46 | 2017 | Alexander Duncan, Ph.D. Chief Technology Officer and Head of Research | 314.7K | 175.0K | — | 307.1K | — | 61.5K | 858.2K | 35.78% | ↗ |
| 47 | 2017 | Christine M. Klaskin Vice President, Finance | 250.0K | 105.0K | — | 137.0K | — | 5.5K | 497.5K | 27.54% | ↗ |
| 48 | 2016 | Garo H. Armen, Ph.D. Chief Executive Officer | 575.0K | 485.0K | 481.0K | 1.70M | — | 4.0K | 3.24M | 67.20% | ↗ |
| 49 | 2016 | Robert Stein, Ph.D. Former President, Research Development | 411.6K | 200.0K | 123.4K | 656.9K | — | 167.1K | 1.56M | 50.05% | ↗ |
| 50 | 2016 | Robert Stein, Ph.D. Former President, RD | 411.6K | 200.0K | 123.4K | 656.9K | — | 167.1K | 1.56M | 50.05% | ↗ |
| 51 | 2016 | Karen H. Valentine Chief Legal Officer and General Counsel | 340.0K | 210.0K | 99.8K | 337.3K | — | 6.1K | 993.2K | 44.01% | ↗ |
| 52 | 2016 | Christine M. Klaskin Vice President, Finance | 250.0K | 102.0K | 49.0K | 113.1K | — | 5.5K | 519.6K | 31.20% | ↗ |
| 53 | 2016 | C. Evan Ballantyne Former Chief Financial Officer | 236.0K | — | 50.8K | 197.1K | — | — | 483.9K | 51.23% | ↗ |
| 54 | 2016 | Ozer Baysal Chief Business Officer | 209.0K | 95.0K | 49.0K | 105.1K | — | 3.6K | 461.7K | 33.38% | ↗ |
| 55 | 2015 | Garo H. Armen, Ph.D. Chief Executive Officer | 544.5K | 490.0K | — | 833.1K | — | 8.3K | 1.88M | 44.41% | ↗ |
| 56 | 2015 | C. Evan Ballantyne Former Chief Financial Officer | 179.0K | 86.1K | — | 1.16M | — | — | 1.43M | 81.41% | ↗ |
| 57 | 2015 | C. Evan Ballantyne Former Chief Financial Officer | 179.0K | 86.1K | — | 1.16M | — | — | 1.43M | 81.41% | ↗ |
| 58 | 2015 | Robert Stein, Ph.D. Former President, Research Development | 373.7K | 249.6K | — | 413.1K | — | 101.6K | 1.14M | 36.31% | ↗ |
| 59 | 2015 | Robert Stein, Ph.D. President, RD | 373.7K | 249.6K | — | 413.1K | — | 101.6K | 1.14M | 36.31% | ↗ |
| 60 | 2015 | Robert Stein, Ph.D. Former President, RD | 373.7K | 249.6K | — | 413.1K | — | 101.6K | 1.14M | 36.31% | ↗ |
| 61 | 2015 | Karen H. Valentine Chief Legal Officer and General Counsel | 319.7K | 220.3K | — | 304.3K | — | 12.7K | 856.9K | 35.51% | ↗ |
| 62 | 2015 | Christine M. Klaskin Vice President, Finance | 239.8K | 108.8K | — | 155.5K | — | 11.5K | 515.6K | 30.17% | ↗ |
| 63 | 2015 | Ozer Baysal Chief Business Officer | 209.0K | 92.8K | — | 128.9K | — | 9.4K | 440.1K | 29.29% | ↗ |
| 64 | 2014 | Garo H. Armen, Ph.D. Chief Executive Officer | 502.4K | 420.0K | — | — | — | — | 2.26M | 0.00% | ↗ |
| 65 | 2014 | Robert Stein, Ph.D. President, RD | 323.8K | — | — | 807.1K | 300.0K | 141.6K | 1.57M | 51.32% | ↗ |
| 66 | 2014 | Robert Stein, Ph.D. Former President, Research Development | 323.8K | 300.0K | — | 807.1K | — | 121.6K | 1.55M | 51.98% | ↗ |
| 67 | 2014 | Robert Stein, Ph.D. President, RD | 323.8K | 300.0K | — | 807.1K | — | 121.6K | 1.55M | 51.98% | ↗ |
| 68 | 2014 | Karen H. Valentine Vice President and General Counsel | 289.2K | — | — | 354.2K | 200.0K | 20.7K | 864.1K | 40.99% | ↗ |
| 69 | 2014 | Karen H. Valentine Chief Legal Officer and General Counsel | 289.2K | 200.0K | — | 354.2K | — | — | 843.4K | 42.00% | ↗ |
| 70 | 2014 | Christine M. Klaskin Vice President, Finance | 222.9K | 103.5K | — | — | — | — | 597.4K | 0.00% | ↗ |
| 71 | 2014 | Ozer Baysal Chief Business Officer | 204.3K | 125.4K | — | — | — | — | 591.0K | 0.00% | ↗ |
| 72 | 2013 | Garo H. Armen, Ph.D. Chief Executive Officer | 489.7K | 439.5K | 212.9K | — | — | 10.9K | 1.75M | 12.18% | ↗ |
| 73 | 2013 | Ozer Baysal Chief Business Officer | 183.7K | 108.0K | 106.0K | — | — | — | 694.8K | 15.26% | ↗ |
| 74 | 2013 | Karen H. Valentine Vice President and General Counsel | 256.5K | — | — | 142.4K | 199.3K | 20.0K | 618.2K | 23.03% | ↗ |
| 75 | 2013 | Karen H. Valentine Chief Legal Officer and General Counsel | 256.5K | 199.3K | — | 142.4K | — | — | 598.2K | 23.80% | ↗ |
| 76 | 2013 | Ozer Baysal Chief Business Officer | 183.7K | — | 106.0K | 297.1K | — | 1.0K | 587.8K | 68.58% | ↗ |
| 77 | 2013 | Kerry A. Wentworth Vice President, Clinical, Regulatory and Quality | 267.1K | — | — | 142.4K | 148.4K | 9.4K | 567.2K | 25.10% | ↗ |
| 78 | 2013 | Christine M. Klaskin Vice President, Finance | 215.7K | 145.9K | — | — | — | — | 459.4K | 0.00% | ↗ |
| 79 | 2013 | Christine M. Klaskin Vice President, Finance and Principal Accounting and Financial Officer | 215.7K | — | — | 97.8K | 120.4K | 3.8K | 437.7K | 22.34% | ↗ |
| 80 | 2012 | Garo H. Armen, Ph.D. Chief Executive Officer | 478.1K | — | 615.6K | — | 215.6K | 30.7K | 2.43M | 25.38% | ↗ |
| 81 | 2012 | Karen H. Valentine Vice President and General Counsel | 244.9K | — | 152.6K | 325.7K | 110.6K | 19.6K | 853.4K | 56.05% | ↗ |
| 82 | 2012 | Kerry A. Wentworth Vice President, Clinical, Regulatory and Quality | 260.8K | — | 189.2K | 325.7K | 40.8K | 7.9K | 824.4K | 62.46% | ↗ |
| 83 | 2012 | Christine M. Klaskin Vice President, Finance | 208.5K | — | 123.7K | — | 80.9K | 4.0K | 661.4K | 18.70% | ↗ |
| 84 | 2012 | Christine M. Klaskin Vice President, Finance and Principal Accounting and Financial Officer | 208.5K | — | 123.7K | 244.3K | 22.1K | 4.0K | 602.6K | 61.06% | ↗ |
| 85 | 2012 | Shalini Sharp Former Vice President and Chief Financial Officer | 102.6K | — | 114.9K | — | 25.4K | 7.2K | 250.1K | 45.93% | ↗ |
| 86 | 2011 | Garo H. Armen, Ph.D. Chief Executive Officer | 464.2K | — | 383.2K | 742.1K | 22.8K | 42.6K | 1.65M | 68.00% | ↗ |
| 87 | 2011 | Kerry A. Wentworth Vice President, Clinical, Regulatory and Quality | 254.4K | — | 86.6K | 265.9K | 62.1K | 11.1K | 680.0K | 51.83% | ↗ |
| 88 | 2011 | Shalini Sharp Former Vice President and Chief Financial Officer | 254.4K | — | 75.1K | 217.6K | 65.4K | 22.2K | 634.8K | 46.12% | ↗ |
| 89 | 2011 | Shalini Sharp Vice President and Chief Financial Officer | 254.4K | — | 75.1K | 217.6K | 65.4K | 22.2K | 634.8K | 46.12% | ↗ |
| 90 | 2011 | Karen H. Valentine Vice President and General Counsel | 233.2K | — | 47.5K | 128.3K | 42.0K | 19.1K | 470.1K | 37.40% | ↗ |
| 91 | 2011 | Christine M. Klaskin Vice President, Finance and Principal Accounting Officer | 196.1K | — | 35.8K | 79.1K | 37.6K | 6.0K | 354.5K | 32.39% | ↗ |
| 92 | 2011 | Christine M. Klaskin Vice President, Finance and Principal Accounting and Financial Officer | 196.1K | — | 35.8K | 79.1K | 37.6K | 6.0K | 354.5K | 32.39% | ↗ |
| 93 | 2010 | Garo H. Armen, Ph.D. Chief Executive Officer | 440.0K | — | 253.3K | 210.3K | 5.1K | 37.4K | 946.0K | 49.00% | ↗ |
| 94 | 2010 | Kerry A. Wentworth Vice President, Clinical, Regulatory and Quality | 244.7K | — | 160.3K | 90.1K | 30.9K | 9.8K | 535.8K | 46.73% | ↗ |
| 95 | 2010 | Shalini Sharp Former Vice President and Chief Financial Officer | 244.7K | — | 156.5K | 75.1K | 32.9K | 19.3K | 528.6K | 43.82% | ↗ |
| 96 | 2010 | Shalini Sharp Vice President and Chief Financial Officer | 244.7K | — | 156.5K | 75.1K | 32.9K | 19.3K | 528.6K | 43.82% | ↗ |
| 97 | 2010 | Karen H. Valentine Vice President and General Counsel | 224.3K | — | 106.9K | 45.1K | 22.4K | 16.9K | 415.6K | 36.57% | ↗ |
| 98 | 2010 | Christine M. Klaskin Vice President, Finance and Principal Accounting Officer | 188.6K | — | 93.5K | 45.1K | 19.3K | 5.9K | 352.4K | 39.32% | ↗ |
| 99 | 2010 | Christine M. Klaskin Vice President, Finance and Principal Accounting and Financial Officer | 188.6K | — | 93.5K | 45.1K | 19.3K | 5.9K | 352.4K | 39.32% | ↗ |
| 100 | 2009 | Garo H. Armen, Ph.D. Chief Executive Officer | 440.0K | — | 768.9K | 593.3K | — | 31.6K | 1.83M | 74.28% | ↗ |
| 101 | 2009 | Kerry A. Wentworth Vice President, Clinical, Regulatory and Quality | 240.0K | — | 42.6K | 50.9K | 50.0K | 7.5K | 391.0K | 23.91% | ↗ |
| 102 | 2009 | Shalini Sharp Vice President and Chief Financial Officer | 240.0K | — | 42.6K | 56.6K | — | 5.6K | 344.9K | 28.77% | ↗ |
| 103 | 2009 | Karen H. Valentine Vice President and General Counsel | 220.0K | — | 24.9K | 31.8K | — | 13.5K | 290.2K | 19.53% | ↗ |
| 104 | 2009 | Christine M. Klaskin Vice President, Finance and Principal Accounting Officer | 185.0K | — | 24.6K | 30.8K | — | 4.8K | 245.2K | 22.60% | ↗ |
| 105 | 2008 | Garo H. Armen, Ph.D. Chief Executive Officer | 440.0K | — | 357.7K | 269.7K | — | 34.8K | 1.10M | 56.92% | ↗ |
| 106 | 2008 | Kerry A. Wentworth Vice President, Clinical Operations and Regulatory Affairs | 240.0K | — | 132.5K | 174.1K | — | 22.8K | 569.5K | 53.85% | ↗ |
| 107 | 2008 | Kerry A. Wentworth Vice President, Clinical, Regulatory and Quality | 240.0K | — | 138.5K | 68.8K | — | 22.8K | 470.1K | 44.09% | ↗ |
| 108 | 2008 | Shalini Sharp Vice President and Chief Financial Officer | 240.0K | — | 148.8K | 68.8K | — | 10.4K | 467.9K | 46.49% | ↗ |
| 109 | 2008 | Karen H. Valentine Vice President and General Counsel | 220.0K | — | 94.0K | 52.9K | — | 19.8K | 386.7K | 37.98% | ↗ |
| 110 | 2008 | Christine M. Klaskin Vice President, Finance and Principal Accounting Officer | 185.0K | — | 88.1K | 52.9K | — | 9.3K | 335.2K | 42.06% | ↗ |
| 111 | 2007 | Garo H. Armen, Ph.D. Chief Executive Officer | 440.0K | — | 268.1K | 339.1K | 55.0K | 35.8K | 1.14M | 53.36% | ↗ |
| 112 | 2007 | Kerry A. Wentworth Vice President, Clinical, Regulatory and Quality | 220.0K | — | 30.8K | 258.8K | 22.0K | 12.7K | 544.3K | 53.22% | ↗ |
| 113 | 2007 | Shalini Sharp Vice President and Chief Financial Officer | 240.0K | — | 31.2K | 178.5K | 24.0K | 7.5K | 481.3K | 43.58% | ↗ |
| 114 | 2007 | Roman M. Chicz, Ph.D. Former Sr. Vice President, Research and Development | 115.1K | — | — | 86.6K | — | 232.9K | 434.6K | 19.92% | ↗ |
| 115 | 2007 | Kerry A. Wentworth Vice President, Clinical Operations and Regulatory Affairs | 220.0K | — | 22.8K | 133.6K | 22.0K | 12.7K | 411.0K | 38.04% | ↗ |
| 116 | 2007 | Christine M. Klaskin Vice President, Finance and Principal Accounting Officer | 185.0K | — | 16.9K | 78.5K | 13.9K | 8.0K | 302.3K | 31.56% | ↗ |
| 117 | 2007 | Karen H. Valentine Vice President and General Counsel | — | — | — | — | — | — | — | — | ↗ |
| 118 | 2006 | Garo H. Armen, Ph.D. Chief Executive Officer | 440.0K | — | — | 940.4K | — | 39.9K | 1.42M | 66.21% | ↗ |
| 119 | 2006 | Garo H. Armen, Ph.D. Chief Executive Officer | 440.0K | — | — | — | — | 39.9K | 1.42M | 0.00% | ↗ |
| 120 | 2006 | Peter Thornton Former Sr. Vice President and Chief Financial Officer | 229.9K | — | — | 335.0K | — | 43.1K | 608.0K | 55.09% | ↗ |
| 121 | 2006 | Roman M. Chicz, Ph.D. Former Sr. Vice President, Research and Development | 284.6K | — | — | 192.8K | 85.5K | 12.0K | 574.9K | 33.53% | ↗ |
| 122 | 2006 | Roman M. Chicz, Ph.D. Sr. Vice President, Research and Development | 284.6K | 85.5K | — | 192.8K | — | 12.0K | 574.9K | 33.53% | ↗ |
| 123 | 2006 | Renu Gupta, M.D. Former Senior Vice President, Development | 250.1K | — | — | 220.4K | — | 30.4K | 500.9K | 44.00% | ↗ |
| 124 | 2006 | Bruce A. Leicher Former Vice President, General Counsel and Secretary | 291.4K | 70.0K | — | 90.7K | — | 13.2K | 465.4K | 19.49% | ↗ |
| 125 | 2006 | Kerry A. Wentworth Vice President, Clinical Operations and Regulatory Affairs | 204.0K | — | 3.3K | 91.6K | 52.6K | 14.9K | 366.4K | 25.90% | ↗ |
| 126 | 2006 | Kerry A. Wentworth Vice President, Clinical Operations and Regulatory Affairs | 203.3K | 52.6K | 3.3K | 91.6K | — | 14.9K | 365.7K | 25.95% | ↗ |
| 127 | 2006 | Shalini Sharp Vice President and Chief Financial Officer | 181.9K | — | 3.3K | 80.4K | 48.0K | 10.7K | 324.4K | 25.82% | ↗ |
| 128 | 2006 | Shalini Sharp Vice President and Chief Financial Officer | 181.9K | 48.0K | 3.3K | 80.4K | — | 10.7K | 324.4K | 25.82% | ↗ |
| 129 | 2006 | Christine M. Klaskin Vice President, Finance and Principal Accounting Officer | 156.8K | — | 2.0K | 38.9K | 26.0K | 9.9K | 233.6K | 17.50% | ↗ |
| 130 | 2006 | Karen H. Valentine Vice President and General Counsel | — | — | — | — | — | — | — | — | ↗ |
| 131 | 2005 | Russell H. Herndon President, Commercial Operations | — | — | — | — | — | 88.6K | 88.6K | 0.00% | ↗ |
| 132 | 2005 | Garo H. Armen, Ph.D. Chairman and Chief Executive Officer | — | — | — | — | — | 8.0K | 8.0K | 0.00% | ↗ |
| 133 | 2005 | Renu Gupta, M.D. Senior Vice President | — | — | — | — | — | 5.1K | 5.1K | 0.00% | ↗ |
| 134 | 2005 | Roman Chicz, Ph.D. Senior Vice President | — | — | — | — | — | 4.8K | 4.8K | 0.00% | ↗ |
| 135 | 2005 | Peter Thornton Senior Vice President and Chief Financial Officer | — | — | — | — | — | 1.8K | 1.8K | 0.00% | ↗ |
| 136 | 2005 | Bruce A. Leicher Vice President and General Counsel | — | — | — | — | — | 118.00 | 118.00 | 0.00% | ↗ |
| 137 | 2004 | Garo H. Armen, Ph.D. Chairman and Chief Executive Officer | 420.0K | 174.3K | — | — | — | — | 594.3K | 0.00% | ↗ |
| 138 | 2004 | Russell H. Herndon President, Commercial Operations | 325.0K | 104.0K | — | — | — | — | 429.0K | 0.00% | ↗ |
| 139 | 2004 | Renu Gupta, M.D. Senior Vice President | 284.4K | 117.0K | — | — | — | — | 401.4K | 0.00% | ↗ |
| 140 | 2004 | Peter Thornton Senior Vice President and Chief Financial Officer | 130.8K | 49.6K | — | — | — | 50.0K | 230.4K | 0.00% | ↗ |
| 141 | 2004 | Peter Thornton Senior Vice President and Chief Financial Officer | — | — | — | — | — | 50.3K | 50.3K | 0.00% | ↗ |
| 142 | 2004 | Russell H. Herndon President, Commercial Operations | — | — | — | — | — | 11.5K | 11.5K | 0.00% | ↗ |
| 143 | 2004 | Garo H. Armen, Ph.D. Chairman and Chief Executive Officer | — | — | — | — | — | 7.4K | 7.4K | 0.00% | ↗ |
| 144 | 2004 | Renu Gupta, M.D. Senior Vice President | — | — | — | — | — | 1.8K | 1.8K | 0.00% | ↗ |
| 145 | 2004 | Roman Chicz, Ph.D. Senior Vice President | — | — | — | — | — | 599.00 | 599.00 | 0.00% | ↗ |
| 146 | 2003 | Garo H. Armen, Ph.D. Chairman and Chief Executive Officer | 400.0K | 170.0K | — | — | — | — | 570.0K | 0.00% | ↗ |
| 147 | 2003 | Russell H. Herndon President, Commercial Operations | 325.0K | 65.0K | — | — | — | — | 390.0K | 0.00% | ↗ |
| 148 | 2003 | Neal Gordon, Ph.D. Senior Vice President | 214.9K | 35.0K | — | — | — | — | 249.9K | 0.00% | ↗ |
| 149 | 2003 | Jeff D. Clark | 187.8K | 40.0K | — | — | — | — | 227.8K | 0.00% | ↗ |
| 150 | 2003 | Renu Gupta, M.D. Senior Vice President | 42.3K | 30.0K | — | — | — | — | 72.3K | 0.00% | ↗ |
| 151 | 2003 | Renu Gupta, M.D. Senior Vice President | — | — | — | — | — | 25.2K | 25.2K | 0.00% | ↗ |
| 152 | 2003 | Russell H. Herndon President, Commercial Operations | — | — | — | — | — | 10.9K | 10.9K | 0.00% | ↗ |
| 153 | 2003 | Garo H. Armen, Ph.D. Chairman and Chief Executive Officer | — | — | — | — | — | 6.9K | 6.9K | 0.00% | ↗ |
| 154 | 2002 | Garo H. Armen, Ph.D. Chairman and Chief Executive Officer | 400.0K | 120.0K | — | — | — | — | 520.0K | 0.00% | ↗ |
| 155 | 2002 | Russell H. Herndon President, Commercial Operations | 325.3K | 100.0K | — | — | — | — | 425.3K | 0.00% | ↗ |
| 156 | 2002 | Russell H. Herndon President and Chief Operating Officer | 325.3K | 100.0K | — | — | — | — | 425.3K | 0.00% | ↗ |
| 157 | 2002 | Elma Hawkins, Ph.D. Vice Chairman | 275.0K | 55.0K | — | — | — | 56.9K | 386.9K | 0.00% | ↗ |
| 158 | 2002 | Neal Gordon, Ph.D. Senior Vice President | 200.0K | 35.0K | — | — | — | — | 235.0K | 0.00% | ↗ |
| 159 | 2001 | Russell H. Herndon President and Chief Operating Officer | 312.5K | 93.8K | — | — | — | — | 406.3K | 0.00% | ↗ |
| 160 | 2001 | Russell H. Herndon President, Commercial Operations | 312.5K | 93.8K | — | — | — | — | 406.3K | 0.00% | ↗ |
| 161 | 2001 | Garo H. Armen, Ph.D. Chairman and Chief Executive Officer | 150.0K | — | — | — | — | 200.0K | 350.0K | 0.00% | ↗ |
| 162 | 2001 | Elma Hawkins, Ph.D. Vice Chairman | 245.4K | 50.0K | — | — | — | — | 295.4K | 0.00% | ↗ |
| 163 | 2001 | Neal Gordon, Ph.D. Senior Vice President | 182.5K | 30.0K | — | — | — | — | 212.5K | 0.00% | ↗ |
| 164 | 2000 | Garo H. Armen, Ph.D. Chairman and Chief Executive Officer | 150.0K | — | — | — | — | 350.0K | 500.0K | 0.00% | ↗ |
| 165 | 2000 | Elma Hawkins, Ph.D. Vice Chairman | 211.8K | 40.0K | — | — | — | — | 251.8K | 0.00% | ↗ |
| 166 | 2000 | Neal Gordon, Ph.D. Senior Vice President | 156.0K | 20.0K | — | — | — | — | 176.0K | 0.00% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Garo H. Armen | Founder, Interim CFO, Principal Financial Officer, CEO & Executive Chairman | 1M | — |
| Steven J. O'Day | Chief Medical Officer | 902.8K | — |
| Jennifer S. Buell | Director and President & Chief Executive Officer of MiNK Therapeutics | — | — |
| Kamel Djazouli | Head of Medical Affairs | — | — |
| Robin G. Taylor | Chief Commercial Officer | — | — |
| Stefanie Perna-Nacar | Chief Communications & Government Relations Officer | — | female |
| Todd Jude Yancey | Member of Advisory Board & Chief Strategic Advisor | — | — |
| Tracy Mazza Clemente | Chief People Officer | — | female |
| Austin Charette | Senior Director, Financial Reporting and Compliance & Principal Accounting Officer | — | male |
| Zack Armen | Vice President of Investor Relations & Corporate Development | — | male |
| Craig Winter | Chief Information Officer | — | — |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for AGEN
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
